Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 28;2(2):CD008834.
doi: 10.1002/14651858.CD008834.pub4.

Antiplatelet agents for chronic kidney disease

Patrizia Natale  1   2   3 , Suetonia C Palmer  4 , Valeria M Saglimbene  1   2 , Marinella Ruospo  1   2 , Mona Razavian  5 , Jonathan C Craig  2   6 , Meg J Jardine  7 , Angela C Webster  2   8 , Giovanni Fm Strippoli  1   2   6
Affiliations

Antiplatelet agents for chronic kidney disease

Patrizia Natale et al. Cochrane Database Syst Rev. .

Abstract

Background: Antiplatelet agents are widely used to prevent cardiovascular events. The risks and benefits of antiplatelet agents may be different in people with chronic kidney disease (CKD) for whom occlusive atherosclerotic events are less prevalent, and bleeding hazards might be increased. This is an update of a review first published in 2013.

Objectives: To evaluate the benefits and harms of antiplatelet agents in people with any form of CKD, including those with CKD not receiving renal replacement therapy, patients receiving any form of dialysis, and kidney transplant recipients.

Search methods: We searched the Cochrane Kidney and Transplant Register of Studies up to 13 July 2021 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.

Selection criteria: We selected randomised controlled trials of any antiplatelet agents versus placebo or no treatment, or direct head-to-head antiplatelet agent studies in people with CKD. Studies were included if they enrolled participants with CKD, or included people in broader at-risk populations in which data for subgroups with CKD could be disaggregated.

Data collection and analysis: Four authors independently extracted data from primary study reports and any available supplementary information for study population, interventions, outcomes, and risks of bias. Risk ratios (RR) and 95% confidence intervals (CI) were calculated from numbers of events and numbers of participants at risk which were extracted from each included study. The reported RRs were extracted where crude event rates were not provided. Data were pooled using the random-effects model. Confidence in the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.

Main results: We included 113 studies, enrolling 51,959 participants; 90 studies (40,597 CKD participants) compared an antiplatelet agent with placebo or no treatment, and 29 studies (11,805 CKD participants) directly compared one antiplatelet agent with another. Fifty-six new studies were added to this 2021 update. Seven studies originally excluded from the 2013 review were included, although they had a follow-up lower than two months. Random sequence generation and allocation concealment were at low risk of bias in 16 and 22 studies, respectively. Sixty-four studies reported low-risk methods for blinding of participants and investigators; outcome assessment was blinded in 41 studies. Forty-one studies were at low risk of attrition bias, 50 studies were at low risk of selective reporting bias, and 57 studies were at low risk of other potential sources of bias. Compared to placebo or no treatment, antiplatelet agents probably reduces myocardial infarction (18 studies, 15,289 participants: RR 0.88, 95% CI 0.79 to 0.99, I² = 0%; moderate certainty). Antiplatelet agents has uncertain effects on fatal or nonfatal stroke (12 studies, 10.382 participants: RR 1.01, 95% CI 0.64 to 1.59, I² = 37%; very low certainty) and may have little or no effect on death from any cause (35 studies, 18,241 participants: RR 0.94, 95 % CI 0.84 to 1.06, I² = 14%; low certainty). Antiplatelet therapy probably increases major bleeding in people with CKD and those treated with haemodialysis (HD) (29 studies, 16,194 participants: RR 1.35, 95% CI 1.10 to 1.65, I² = 12%; moderate certainty). In addition, antiplatelet therapy may increase minor bleeding in people with CKD and those treated with HD (21 studies, 13,218 participants: RR 1.55, 95% CI 1.27 to 1.90, I² = 58%; low certainty). Antiplatelet treatment may reduce early dialysis vascular access thrombosis (8 studies, 1525 participants) RR 0.52, 95% CI 0.38 to 0.70; low certainty). Antiplatelet agents may reduce doubling of serum creatinine in CKD (3 studies, 217 participants: RR 0.39, 95% CI 0.17 to 0.86, I² = 8%; low certainty). The treatment effects of antiplatelet agents on stroke, cardiovascular death, kidney failure, kidney transplant graft loss, transplant rejection, creatinine clearance, proteinuria, dialysis access failure, loss of primary unassisted patency, failure to attain suitability for dialysis, need of intervention and cardiovascular hospitalisation were uncertain. Limited data were available for direct head-to-head comparisons of antiplatelet drugs, including prasugrel, ticagrelor, different doses of clopidogrel, abciximab, defibrotide, sarpogrelate and beraprost.

Authors' conclusions: Antiplatelet agents probably reduced myocardial infarction and increased major bleeding, but do not appear to reduce all-cause and cardiovascular death among people with CKD and those treated with dialysis. The treatment effects of antiplatelet agents compared with each other are uncertain.

Trial registration: ClinicalTrials.gov NCT01709994 NCT01155765 NCT01090037 NCT00979589 NCT00050817 NCT00776828 NCT00067119 NCT03289520 NCT00089895 NCT00110448 NCT01252056 NCT02578537 NCT01225562 NCT01328470 NCT02163954 NCT02406911 NCT00391872 NCT00234585 NCT02022748 NCT00526474 NCT00527943 NCT00097591 NCT00496769 NCT01082874 NCT00611286 NCT01173666 NCT00059306 NCT00320008 NCT00699998 NCT02663713 NCT03387826 NCT03796156 NCT02895113 NCT01198379 NCT01743014 NCT02394145 NCT02459288 NCT03039205 NCT03150667 NCT03649711 NCT01165567 NCT02294643 NCT01869881 NCT03357874.

PubMed Disclaimer

Conflict of interest statement

Editorial contributions

  1. Sign‐off Editor (final editorial decision): Dr Elisabeth Hodson

Figures

1
1
Study flow diagram; study identification and selection process.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies
3
3
Funnel plot of comparison of antiplatelet agents versus control for the outcome of fatal or nonfatal myocardial infarction
1.1
1.1. Analysis
Comparison 1: Antiplatelet agents versus control, Outcome 1: Fatal or nonfatal myocardial infarction
1.2
1.2. Analysis
Comparison 1: Antiplatelet agents versus control, Outcome 2: Fatal or nonfatal stroke
1.3
1.3. Analysis
Comparison 1: Antiplatelet agents versus control, Outcome 3: Death (any cause)
1.4
1.4. Analysis
Comparison 1: Antiplatelet agents versus control, Outcome 4: Haemorrhagic stroke
1.5
1.5. Analysis
Comparison 1: Antiplatelet agents versus control, Outcome 5: Cardiovascular death
1.6
1.6. Analysis
Comparison 1: Antiplatelet agents versus control, Outcome 6: Fatal bleeding
1.7
1.7. Analysis
Comparison 1: Antiplatelet agents versus control, Outcome 7: Major bleeding
1.8
1.8. Analysis
Comparison 1: Antiplatelet agents versus control, Outcome 8: Minor bleeding
1.9
1.9. Analysis
Comparison 1: Antiplatelet agents versus control, Outcome 9: Kidney failure
1.10
1.10. Analysis
Comparison 1: Antiplatelet agents versus control, Outcome 10: Doubling of serum creatinine
1.11
1.11. Analysis
Comparison 1: Antiplatelet agents versus control, Outcome 11: Kidney transplant graft loss
1.12
1.12. Analysis
Comparison 1: Antiplatelet agents versus control, Outcome 12: Transplant rejection
1.13
1.13. Analysis
Comparison 1: Antiplatelet agents versus control, Outcome 13: Creatinine clearance
1.14
1.14. Analysis
Comparison 1: Antiplatelet agents versus control, Outcome 14: Proteinuria
1.15
1.15. Analysis
Comparison 1: Antiplatelet agents versus control, Outcome 15: Dialysis access failure (thrombosis or loss of patency)
1.16
1.16. Analysis
Comparison 1: Antiplatelet agents versus control, Outcome 16: Early access thrombosis (before 8 weeks)
1.17
1.17. Analysis
Comparison 1: Antiplatelet agents versus control, Outcome 17: Loss of primary unassisted patency
1.18
1.18. Analysis
Comparison 1: Antiplatelet agents versus control, Outcome 18: Failure to attain suitability for dialysis
1.19
1.19. Analysis
Comparison 1: Antiplatelet agents versus control, Outcome 19: Need for intervention to attain patency or assist maturation
1.20
1.20. Analysis
Comparison 1: Antiplatelet agents versus control, Outcome 20: Hospitalisation (any cause)
1.21
1.21. Analysis
Comparison 1: Antiplatelet agents versus control, Outcome 21: Cardiovascular hospitalisation
1.22
1.22. Analysis
Comparison 1: Antiplatelet agents versus control, Outcome 22: Treatment withdrawal
2.1
2.1. Analysis
Comparison 2: Prasugrel versus clopidogrel, Outcome 1: Fatal or nonfatal myocardial infarction
2.2
2.2. Analysis
Comparison 2: Prasugrel versus clopidogrel, Outcome 2: Death (any cause)
2.3
2.3. Analysis
Comparison 2: Prasugrel versus clopidogrel, Outcome 3: Cardiovascular death
2.4
2.4. Analysis
Comparison 2: Prasugrel versus clopidogrel, Outcome 4: Major bleeding
2.5
2.5. Analysis
Comparison 2: Prasugrel versus clopidogrel, Outcome 5: Minor bleeding
3.1
3.1. Analysis
Comparison 3: Ticagrelor versus clopidogrel, Outcome 1: Fatal or nonfatal myocardial infarction
3.2
3.2. Analysis
Comparison 3: Ticagrelor versus clopidogrel, Outcome 2: Fatal or nonfatal stroke
3.3
3.3. Analysis
Comparison 3: Ticagrelor versus clopidogrel, Outcome 3: Death (any cause)
3.4
3.4. Analysis
Comparison 3: Ticagrelor versus clopidogrel, Outcome 4: Cardiovascular death
3.5
3.5. Analysis
Comparison 3: Ticagrelor versus clopidogrel, Outcome 5: Fatal bleeding
3.6
3.6. Analysis
Comparison 3: Ticagrelor versus clopidogrel, Outcome 6: Major bleeding
3.7
3.7. Analysis
Comparison 3: Ticagrelor versus clopidogrel, Outcome 7: Minor bleeding
3.8
3.8. Analysis
Comparison 3: Ticagrelor versus clopidogrel, Outcome 8: Treatment withdrawal
4.1
4.1. Analysis
Comparison 4: Clopidogrel (low dose) versus clopidogrel (high dose), Outcome 1: Haemorragic stroke
4.2
4.2. Analysis
Comparison 4: Clopidogrel (low dose) versus clopidogrel (high dose), Outcome 2: Cardiovascular death
5.1
5.1. Analysis
Comparison 5: Abciximab versus tirofiban, Outcome 1: Fatal or nonfatal myocardial infarction
5.2
5.2. Analysis
Comparison 5: Abciximab versus tirofiban, Outcome 2: Death (any cause)
6.1
6.1. Analysis
Comparison 6: Defibrotide versus dypiridamole, Outcome 1: Death (any cause)
6.2
6.2. Analysis
Comparison 6: Defibrotide versus dypiridamole, Outcome 2: Cardiovascular death
6.3
6.3. Analysis
Comparison 6: Defibrotide versus dypiridamole, Outcome 3: Fatal bleeding
6.4
6.4. Analysis
Comparison 6: Defibrotide versus dypiridamole, Outcome 4: Kidney transplant graft loss
7.1
7.1. Analysis
Comparison 7: Cilostazol versus sarpogrelate, Outcome 1: Major bleeding
8.1
8.1. Analysis
Comparison 8: Beraprost versus cilostazol or sarpogrelate, Outcome 1: Fatal or nonfatal myocardial infarction
8.2
8.2. Analysis
Comparison 8: Beraprost versus cilostazol or sarpogrelate, Outcome 2: Fatal or nonfatal stroke
8.3
8.3. Analysis
Comparison 8: Beraprost versus cilostazol or sarpogrelate, Outcome 3: Death (any cause)
8.4
8.4. Analysis
Comparison 8: Beraprost versus cilostazol or sarpogrelate, Outcome 4: Cardiovascular death
8.5
8.5. Analysis
Comparison 8: Beraprost versus cilostazol or sarpogrelate, Outcome 5: Fatal bleeding
9.1
9.1. Analysis
Comparison 9: Primary/secondary prevention for fatal/non fatal myocardial infarction (subgroup analysis), Outcome 1: Secondary prevention
10.1
10.1. Analysis
Comparison 10: Sensitivity analysis (adequate allocation concealment), Outcome 1: Fatal or nonfatal myocardial infarction
10.2
10.2. Analysis
Comparison 10: Sensitivity analysis (adequate allocation concealment), Outcome 2: Death (any cause)
10.3
10.3. Analysis
Comparison 10: Sensitivity analysis (adequate allocation concealment), Outcome 3: Cardiovascular death
10.4
10.4. Analysis
Comparison 10: Sensitivity analysis (adequate allocation concealment), Outcome 4: Major bleeding
11.1
11.1. Analysis
Comparison 11: Sensitivity analysis (low risk of attrition), Outcome 1: Fatal or nonfatal myocardial infarction
11.2
11.2. Analysis
Comparison 11: Sensitivity analysis (low risk of attrition), Outcome 2: Death (any cause)
11.3
11.3. Analysis
Comparison 11: Sensitivity analysis (low risk of attrition), Outcome 3: Cardiovascular death
11.4
11.4. Analysis
Comparison 11: Sensitivity analysis (low risk of attrition), Outcome 4: Major bleeding
12.1
12.1. Analysis
Comparison 12: Stroke (subgroup analysis), Outcome 1: Stage of CKD
12.2
12.2. Analysis
Comparison 12: Stroke (subgroup analysis), Outcome 2: Diabetes
12.3
12.3. Analysis
Comparison 12: Stroke (subgroup analysis), Outcome 3: Sex
12.4
12.4. Analysis
Comparison 12: Stroke (subgroup analysis), Outcome 4: Duration of intervention
13.1
13.1. Analysis
Comparison 13: Minor bleeding (subgroup analysis), Outcome 1: Stage of CKD
13.2
13.2. Analysis
Comparison 13: Minor bleeding (subgroup analysis), Outcome 2: Diabetes
13.3
13.3. Analysis
Comparison 13: Minor bleeding (subgroup analysis), Outcome 3: Sex
13.4
13.4. Analysis
Comparison 13: Minor bleeding (subgroup analysis), Outcome 4: Duration of intervention
14.1
14.1. Analysis
Comparison 14: Dialysis access failure (subgroup analysis), Outcome 1: Diabetes
14.2
14.2. Analysis
Comparison 14: Dialysis access failure (subgroup analysis), Outcome 2: Sex
14.3
14.3. Analysis
Comparison 14: Dialysis access failure (subgroup analysis), Outcome 3: Duration of intervention
15.1
15.1. Analysis
Comparison 15: Failure to attain suitability for dialysis (subgroup analysis), Outcome 1: Duration of intervention
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

AASER 2017 {published data only}
    1. Goicoechea M, Vinuesa MS, Quiroga B, Verdalles U, Morales E, De Sequera P, et al.Aspirin treatment in primary cardiovascular prevention and renal disease progression in CKD patients: a randomized clinical trials (AASER study) [abstract no: FR-PO1065]. Journal of the American Society of Nephrology 2017;28(Abstract Suppl):B5. [EMBASE: 633704620]
    1. Goicoechea M, Vinuesa SG, Quiroga B, Verde E, Bernis C, Morales E, et al.Aspirin for primary prevention of cardiovascular disease and renal disease progression in chronic kidney disease patients: a multicenter randomized clinical trial (AASER Study). Cardiovascular Drugs & Therapy 2018;32(3):255-63. [MEDLINE: ] - PubMed
    1. Goicoechea M, Sanchez-Nino MD, Ortiz A, Vinuesa MS, Quiroga B, Morales E, et al.Low dose aspirin increases 15-epi-lipoxin a4 levels in CKD patients [abstract no: SA-PO186]. Journal of the American Society of Nephrology 2017;28(Abstract Suppl):726. [EMBASE: 633701100]
    1. Goicoechea M, Sanchez-Nino MD, Ortiz A, Garcia de Vinuesa S, Quiroga B, Bernis C, et al.Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients. Prostaglandins Leukotrienes & Essential Fatty Acids 2017;125:8-13. [MEDLINE: ] - PubMed
Abacilar 2015 {published data only}
    1. Abacilar AF, Atalay H, Dogan OF.Oral prostacycline analog and clopidogrel combination provides early maturation and long-term survival after arteriovenous fistula creation: a randomized controlled study. Indian Journal of Nephrology 2015;25(3):136-42. [MEDLINE: ] - PMC - PubMed
Abdul‐Rahman 2007 {published data only}
    1. Abdul-Rahman IS, Al-Howaish AK.Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study. Hong Kong Journal of Nephrology 2007;9(1):23-30. [EMBASE: 2007269768]
Alexopoulos 2011 {published data only}
    1. Alexopoulos D, Panagiotou A, Xanthopoulou I, Komninakis D, Kassimis G, Davlouros P, et al.Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. Journal of Thrombosis & Haemostasis 2011;9(12):2379-85. [MEDLINE: ] - PubMed
    1. Xanthopoulou I, Panagiotou A, Komninakis D, Davlouros P, Kassimis G, Fourtounas K, et al.Prasugrel versus double clopidpogrel maintenance dose in patients on chronic haemodialysis and high on clopidogrel platelet reactivity [abstract no: P2438]. European Heart Journal 2011;32(Suppl 1):417. [EMBASE: 70534608]
Anderson 1974 {published data only}
    1. Anderson M, Dewar P, Fleming LB, Hacking PM, Morley AR, Murray S, et al.A controlled trial of dipyridamole in human renal transplantation and an assessment of platelet function studies in rejection. Clinical Nephrology 1974;2(3):93-9. [MEDLINE: ] - PubMed
Andrassy 1974 {published data only}
    1. Andrassy K, Malluche H, Bornefeld H, Comberg M, Ritz E, Jesdinsky H, et al.Prevention of p.o. clotting of av. cimino fistulae with acetylsalicyl acid: results of a prospective double blind study. Klinische Wochenschrift 1974;52(7):348-9. [MEDLINE: ] - PubMed
ATACAS 2008 {published data only}
    1. Di Franco A, Gaudino M, Girardi LN.Considerations about the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial. Journal of Thoracic Disease 2016;8(7):E599. [MEDLINE: ] - PMC - PubMed
    1. Myles PS, Smith J, Knight J, Cooper DJ, Silbert B, McNeil J, et al.Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial: rationale and design. American Heart Journal 2008;155(2):224-30. [MEDLINE: ] - PubMed
    1. Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, et al.Stopping vs. continuing aspirin before coronary artery surgery. New England Journal of Medicine 2016;374(8):728-37. [MEDLINE: ] - PubMed
    1. Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, et al.Tranexamic acid in patients undergoing coronary-artery surgery [Erratum for: N Engl J Med. 2017 Jan 12;376(2):136-148; PMID: 27774838]. New England Journal of Medicine 2017;376(2):136-48. [MEDLINE: ] - PubMed
    1. Myles PS, Smith JA, Kasza J, Silbert B, Jayarajah M, Painter T, et al.Aspirin in coronary artery surgery: 1-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery trial. Journal of Thoracic & Cardiovascular Surgery 2019;157(2):633-40. [MEDLINE: ] - PubMed
CASSIOPEIR 2014 {published data only}
    1. Fujita T, Yu X, Kim S, Nakamoto H, Origasa H, Kurumatani H, et al.Effects of sustained-release beraprost sodium in patients with primary glomerular disease or nephrosclerosis: the CASSIOPEIR study [abstract no: SA-PO1096]. Journal of the American Society of Nephrology 2015;26(Abstract Suppl):4B. [CENTRAL: CN-01657821]
    1. Nakamoto H, Fujita T, Origasa H, Isono M, Kurumatani H, Okada K, et al.A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design. BMC Nephrology 2014;15:153. [MEDLINE: ] - PMC - PubMed
    1. Nakamoto H, Yu XQ, Kim S, Origasa H, Zheng H, Chen J, et al.Effects of sustained-release beraprost in patients with primary glomerular disease or nephrosclerosis: CASSIOPEIR study results. Therapeutic Apheresis & Dialysis 2020;24(1):42-55. [MEDLINE: ] - PubMed
Chan 1987 {published data only}
    1. Chan MK, Kwan SY, Chan KW, Yeung CK.Controlled trial of antiplatelet agents in mesangial IgA glomerulonephritis. American Journal of Kidney Diseases 1987;9(5):417-21. [MEDLINE: ] - PubMed
CHANCE 2013 {published data only}
    1. Jing J, Meng X, Zhao X, Liu L, Wang A, Pan Y, et al.Dual antiplatelet therapy in transient ischemic attack and minor stroke with different infarction patterns: subgroup analysis of the CHANCE randomized clinical trial. JAMA Neurology 2018;75(6):711-9. [MEDLINE: ] - PMC - PubMed
    1. Li J, Wang Y, Lin J, Wang D, Wang A, Zhao X, et al.Soluble CD40L is a useful marker to predict future strokes in patients with minor stroke and transient ischemic attack. Stroke 2015;46(7):1990-2. [MEDLINE: ] - PubMed
    1. Li J, Zhao X, Meng X, Lin J, Liu L, Wang C, et al.High-sensitive C-reactive protein predicts recurrent stroke and poor functional outcome: subanalysis of the clopidogrel in high-risk patients with acute nondisabling cerebrovascular events trial. Stroke 2016;47(8):2025-30. [MEDLINE: ] - PubMed
    1. Lin Y, Wang A, Li J, Lin J, Wang D, Meng X, et al.Impact of glycemic control on efficacy of clopidogrel in transient ischemic attack or minor stroke patients with CYP2C19 genetic variants. Stroke 2017;48(4):998-1004. [MEDLINE: ] - PubMed
    1. Liu L, Wong KS, Leng X, Pu Y, Wang Y, Jing J, et al.Dual antiplatelet therapy in stroke and ICAS: subgroup analysis of CHANCE. Neurology 2015;85(13):1154-62. [MEDLINE: ] - PMC - PubMed
CHARISMA 2006 {published and unpublished data}
    1. Bangalore S, Bhatt DL, Steg PG, Weber MA, Boden WE, Hamm CW, et al.beta-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circulation: Cardiovascular Quality & Outcomes 2014;7(6):872-81. [MEDLINE: ] - PubMed
    1. Berger PB, Bhatt DL, Fuster V, Steg PG, Fox KA, Shao M, et al.Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation 2010;121(23):2575-83. [MEDLINE: ] - PubMed
    1. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, et al.Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. Journal of the American College of Cardiology 2007;49(19):1982-8. [MEDLINE: ] - PubMed
    1. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al.A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial [Erratum in: Am Heart J. 2006 Jan;151(1):247]. American Heart Journal 2005;150(3):401. [MEDLINE: ] - PubMed
    1. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al.Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New England Journal of Medicine 2006;354(16):1706-17. [MEDLINE: ] - PubMed
Cheng 1998a {published data only}
    1. Cheng IK, Fang GX, Wong MC, Ji YL, Chan KW, Yeung HW.A randomized prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA nephropathy. Nephrology 1998;4(1-2):19-26. [EMBASE: 28282953]
    1. Cheng IK, Fang GX, Wong MC, Ji YL, Yeung H.A randomised prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA glomerulonephritis (IgAN) [abstract]. In: 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel. 1993:45. [CENTRAL: CN-00550664]
Christopher 1987 {published data only}
    1. Christopher TG, Samels K.A study of aspirin and dipyridamole in slowing the progression of diabetic glomerulosclerosis [abstract]. Kidney International 1987;31(1):194.
    1. Christopher TG, Samels K.A study of the treatment effect of aspirin and dipyridamole in diabetic glomerulosclerosis [abstract]. In: 10th International Congress of Nephrology; 1987 Jul 26-31; London, UK. 1987:56.
CILON‐T 2010 {published data only}
    1. Lee MH, Suh JW, Lee SP, Park KW, Lee HY, Kang HJ, et al.The effect of cilostazol on the antiplatelet efficacy of patients with moderate renal dysfunction: post-hoc analysis of CILON-T (Influence of cilostazol based triple antiplatelet therapy on ischemic complication after drug eluting stent implantation) trial [abstract no: TCT-495]. Journal of the American College of Cardiology 2011;58(20 Suppl 1):B134-5. [EMBASE: 70581865]
    1. Lee SP, Suh JW, Park KW, Lee HY, Kang HJ, Koo BK, et al.Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: a multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease. Trials [Electronic Resource] 2010;11:87. [MEDLINE: ] - PMC - PubMed
    1. Suh JW, Lee SP, Park KW, Lee HY, Kang HJ, Koo BK, et al.Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. Journal of the American College of Cardiology 2011;57(3):280-9. [MEDLINE: ] - PubMed
CREDO 2005 {published and unpublished data}
    1. Aronow HD, Steinhubl SR, Brennan DM, Berger PB, Topol EJ, CREDO Investigators.Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal 2009;157(2):369-74. [MEDLINE: ] - PubMed
    1. Beinart SC, Kolm P, Veledar E, Zhang Z, Mahoney EM, Bouin O, et al.Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Journal of the American College of Cardiology 2005;46(5):761-9. [MEDLINE: ] - PubMed
    1. Best PJ, Steinhubl SR, Berger PB, Dasgupta A, Brennan DM, Szczech LA, et al.The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal 2008;155(4):687-93. [MEDLINE: ] - PubMed
    1. Brener SJ, Steinhubl SR, Berger PB, Brennan DM, Topol EJ, CREDO Investigators.Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial. Journal of Invasive Cardiology 2007;19(7):287-90. [MEDLINE: ] - PubMed
    1. Ringborg A, Lindgren P, Jonsson B.The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial. European Journal of Health Economics 2005;6(4):354-56, 358-62. [MEDLINE: ] - PubMed
Creek 1990 {published data only}
    1. Creek R.Ticlopidine. Patency of haemodialysis access sites. Guildford Sanofi Winthrop. Internal report 1990.
CURE 2000 {published data only (unpublished sought but not used)}
    1. Berger PB, Steinhubl S.Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: a US perspective. Circulation 2002;106(17):2284-7. [MEDLINE: ] - PubMed
    1. Gerschutz GP, Bhatt DL, Clopidogrel in Unstable Angina to Prevent Recurrent Events study.The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable? American Heart Journal 2003;145(4):595-601. [MEDLINE: ] - PubMed
    1. Keltai M, Tonelli M, Mann JF, Sitkei E, Lewis BS, Hawken S, et al.Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. European Journal of Cardiovascular Prevention & Rehabilitation 2007;14(2):312-8. [MEDLINE: ] - PubMed
    1. Lewis BS, Mehta SR, Fox KA, Halon DA, Zhao F, Peters RJ, et al.Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. American Heart Journal 2005;150(6):1177-84. [MEDLINE: ] - PubMed
    1. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al.Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358(9281):527-33. [MEDLINE: ] - PubMed
Dash 2013 {published data only}
    1. Dash A, Maiti R, Bandakkanavar TK, Bhaskar A, Prakash J, Pandey BL.Prophylactic add-on antiplatelet therapy in chronic kidney disease with type 2 diabetes mellitus: comparison between clopidogrel and low-dose aspirin. International Journal of Preventive Medicine 2013;4(8):902-10. [MEDLINE: ] - PMC - PubMed
Dember 2005 {published data only}
    1. Dember L, Allon M, Delmez J, Dixon B, Greenberg A, Himmelfarb J, et al.Dialysis access consortium (DAC) fistula trial: progress report and baseline characteristics [abstract no: SA-PO940]. Journal of the American Society of Nephrology 2003;14(Nov):506A. [CENTRAL: CN-00550593]
    1. Dember LM, Beck GJ, Allon M, Delmez JA, Dixon BS, Greenberg A, et al.Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA 2008;299(18):2164-71. [MEDLINE: ] - PMC - PubMed
    1. Dember LM, Kaufman JS, Beck GJ, Dixon BS, Gassman JJ, Greene T, et al.Design of the Dialysis Access Consortium (DAC) clopidogrel prevention of early AV fistula thrombosis trial. Clinical Trials 2005;2(5):413-22. [MEDLINE: ] - PubMed
    1. Dember LM, Kaufman JS, Beck GJ, Dixon BS, Gassman JJ, Greene T, et al.Dialysis access consortium (DAC) trial design: clopidogrel prevention of early AV fistula thrombosis [abstract no: F-PO827]. Journal of the American Society of Nephrology 2002;13(Program & Abstracts):229A. [CENTRAL: CN-00445067]
Dixon 2005 {published data only}
    1. Allon M, Zhang L, Maya ID, Bray MS, Fernandez JR, Dialysis Access Consortium.Association of factor V gene polymorphism with arteriovenous graft failure. American Journal of Kidney Diseases 2012;59(5):682-8. [MEDLINE: ] - PMC - PubMed
    1. Dixon B, Beck G, Meyers C, Kusek J, Feldman H, DAC Study Group.Effect of aspirin (ASA) on primary unassisted graft patency in the Dialysis Access Consortium (DAC) graft trial [abstract no: TH-PO660]. Journal of the American Society of Nephrology 2008;19(Abstract Issue):256A. [CENTRAL: CN-00716048]
    1. Dixon BS, Allon M, Delmez J, Dember L, Greenberg A, Himmelfarb J, et al.Dialysis access consortium (DAC) graft trial: progress report and baseline characteristics [abstract no: SA-PO939]. Journal of the American Society of Nephrology 2003;14(Nov):506A. [CENTRAL: CN-00583294]
    1. Dixon BS, Beck GJ, Dember LM, Depner TA, Gassman JJ, Greene T, et al.Design of the Dialysis Access Consortium (DAC) aggrenox prevention of access stenosis trial. Clinical Trials 2005;2(5):400-12. [MEDLINE: ] - PubMed
    1. Dixon BS, Beck GJ, Dember LM, Vazquez MA, Greenberg A, Delmez JA, et al.Use of aspirin associates with longer primary patency of hemodialysis grafts. Journal of the American Society of Nephrology 2011;22(4):773-81. [MEDLINE: ] - PMC - PubMed
Dmoszynska‐Giannopoulou 1990 {published data only}
    1. Dmoszynska-Giannopoulou A, Janicka L, Sokolowska B, Ksiazek A, Orlowska G, Janicki K.The effect of sulphinpyrazone and alpha-tocopherol on platelet activation and function in haemodialysed patients. International Urology & Nephrology 1990;22(6):561-6. [MEDLINE: ] - PubMed
Dodd 1980 {published data only}
    1. Dodd NJ, Turney JH, Weston MJ.Ticlopidine preserves vascular access for haemodialysis [abstract no: 326F]. In: Proceedings of the VI International Congress of Mediterranean League Against Thrombosis; 1980 Oct 25-26; Montecarlo, Monaco. 1980.
Donadio 1984 {published data only}
    1. Donadio JV, Anderson CF, Mitchell JC, Holley KE, Ilstrup DM, Fuster V.Membranoproliferative glomerulonephritis (MPGN): a prospective clinical trial of platelet inhibitor therapy [abstract]. Kidney International 1983;23(1):121. [CENTRAL: CN-00602010] - PubMed
    1. Donadio JV Jr, Anderson CF, Mitchell JC 3rd, Holley KH, Ilstrup DM, Fuster V, et al.Membranoproliferative glomerulonephritis. A prospective clinical trial of platelet-inhibitor therapy. New England Journal of Medicine 1984;310(22):1421-6. [MEDLINE: ] - PubMed
EARLY ACS 2005 {published data only}
    1. Bagai A, White JA, Lokhnygina Y, Giugliano RP, Van de Werf F, Montalescot G, et al.Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial. American Heart Journal 2013;166(3):466-73. [MEDLINE: ] - PubMed
    1. De Ferrari GM, Van de Werf F, Armstrong P, Bode C, Lewis BS, Tricoci P, et al.Contrast induced nephropathy predicts later mortality among patients with non-ST-segment elevation acute coronary syndrome undergoing PCI: a sub-analysis from the EARLY ACS study [abstract no: P3820]. European Heart Journal 2011;32(Suppl 1):657. [EMBASE: 70535519]
    1. Ezekowitz JA, Bakal JA, Westerhout CM, Giugliano RP, White H, Keltai M, et al.The relationship between meteorological conditions and index acute coronary events in a global clinical trial. International Journal of Cardiology 2013;168(3):2315-21. [MEDLINE: ] - PubMed
    1. Farhan S, Clare RM, Jarai R, Giugliano RP, Lokhnygina Y, Harrington RA, et al.Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: an analysis from EARLY ACS. International Journal of Cardiology 2017;232:264-70. [MEDLINE: ] - PubMed
    1. Farhan S, Clare RM, Jarai R, Newby LK, Morrow D, Giugliano RP, et al.Fasting glucose, NT-proBNP, treatment with glycoprotein IIB/IIIA inhibitors, and outcomes in non-st-segment elevation acute coronary syndromes: an analysis from early ACS [abstract no: A14618]. Circulation 2013;128(22 Suppl 1). [EMBASE: 71340424]
Ell 1982 {published and unpublished data}
    1. Ell S, Mihindukulasuriya JC, O'Brien JR, Polak A, Vernham G.Ticlopidine in the prevention of blockage of fistulae and shunts [abstract no: 332]. Haemostasis 1982;12:180.
EPIC 1994 {published data only}
    1. Aguirre FV, Topol EJ, Anderson KM, Kleiman NS, Weisman HF, FitzPatrick SE, et al.Benefit within patient subgroups receiving c7e3 fab (abciximab) during percutaneous coronary revascularization: subgroup analysis from the EPIC trial. Journal of Invasive Cardiology 1996;8 Suppl B:21-9B. [MEDLINE: ] - PubMed
    1. Aguirre FV, Topol EJ, Ferguson JJ, Anderson K, Blankenship JC, Heuser RR, et al.Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators. Circulation 1995;91(12):2882-90. [MEDLINE: ] - PubMed
    1. Berkowitz SD, Sane DC, Sigmon KN, Shavender JH, Harrington RA, Tcheng JE, et al.Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. Journal of the American College of Cardiology 1998;32(2):311-9. [MEDLINE: ] - PubMed
    1. Blankenship JC, Hellkamp AS, Aguirre FV, Demko SL, Topol EJ, Califf RM.Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. American Journal of Cardiology 1998;81(1):36-40. [MEDLINE: ] - PubMed
    1. Boehrer JD, Kereiakes DJ, Navetta FI, Califf RM, Topol EJ.Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation Prevention of Ischemic Complications. American Journal of Cardiology 1994;74(11):1166-70. [MEDLINE: ] - PubMed
EPILOG 1997 {unpublished data only}
    1. EPILOG Investigators.Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. New England Journal of Medicine 1997;336(24):1689-96. [MEDLINE: ] - PubMed
    1. Ghaffari S, Kereiakes DJ, Lincoff AM, Kelly TA, Timmis GC, Kleiman NS, et al.Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade. American Journal of Cardiology 1998;82(1):7-12. [MEDLINE: ] - PubMed
    1. Kereiakes DJ, Lincoff AM, Miller DP, Tcheng JE, Cabot CF, Anderson KM, et al.Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators. Circulation 1998;97(9):857-64. [MEDLINE: ] - PubMed
    1. Kleiman NS, Lincoff AM, Kereiakes DJ, Miller DP, Aguirre FV, Anderson KM, et al.Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. Circulation 1998;97(19):1912-20. [MEDLINE: ] - PubMed
    1. Lincoff AM, Mark DB, Tcheng JE, Califf RM, Bala MV, Anderson KM, et al.Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation 2000;102(24):2923-9. [MEDLINE: ] - PubMed
EPISTENT 1998 {unpublished data only}
    1. Cho L, Marso SP, Bhatt DL, Topol EJ.Optimizing percutaneous coronary revascularization in diabetic women: analysis from the EPISTENT trial. Journal of Womens Health & Gender-Based Medicine 2000;9(7):741-6. [MEDLINE: ] - PubMed
    1. De Servi S.Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse events. Data from the Evaluation of Platelets IIb/IIIa Inhibitor for Stenting (EPISTENT) trial [Il pretrattamento con ticlopidina nello stent coronarico e associato a significativa riduzione di eventi avversi. Dati dal trial EPISTENT]. Italian Heart Journal Supplement 2001;2(7):805-6. [MEDLINE: ] - PubMed
    1. EPISTENT Investigators.Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352(9122):87-92. [MEDLINE: ] - PubMed
    1. Islam MA, Blankenship JC, Balog C, Iliadis EA, Lincoff AM, Tcheng JE, et al.Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). American Journal of Cardiology 2002;90(9):916-21. [MEDLINE: ] - PubMed
    1. Lincoff AM.Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularization in patients with diabetes mellitus: results of the EPISTENT trial. American Heart Journal 2000;139(2 Pt 2):S46-52. [MEDLINE: ] - PubMed
ETDRS 1992 {unpublished data only}
    1. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA 1992;268(10):1292-300. [MEDLINE: ] - PubMed
EUCLID 2017 {published data only}
    1. Baumgartner I, Norgren L, Fowkes FG, Mulder H, Patel MR, Berger JS, et al.Cardiovascular outcomes after lower extremity endovascular or surgical revascularization: the EUCLID trial. Journal of the American College of Cardiology 2018;72(14):1563-72. [MEDLINE: ] - PubMed
    1. Berger JS, Abramson BL, Lopes RD, Heizer G, Rockhold FW, Baumgartner I, et al.Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial. Vascular Medicine 2018;23(6):523-30. [MEDLINE: ] - PubMed
    1. Haine A, Kavanagh S, Berger JS, Hess CN, Norgren L, Fowkes FG, et al.Sex-specific risks of major cardiovascular and limb events in patients with symptomatic peripheral artery disease. Journal of the American College of Cardiology 2020;75(6):608-17. [MEDLINE: ] - PubMed
    1. Hess CN, Huang Z, Patel MR, Baumgartner I, Berger JS, Blomster JI, et al.Acute limb ischemia in peripheral artery disease. Circulation 2019;140(7):556-65. [MEDLINE: ] - PubMed
    1. Hiatt WR, Fowkes FG, Heizer G, Berger JS, Baumgartner I, Held P, et al.Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. New England Journal of Medicine 2017;376(1):32-40. [MEDLINE: ] - PubMed
FAVOURED 2009 {published data only}
    1. Badve S, Hawley CM, Irish AB, Paul-Brent P.High rate of screening failure in the FAVOURED study [abstract no: PUB345]. Journal of the American Society of Nephrology 2009;20(Abstract Suppl):905A.
    1. Irish A, Dogra G, Mori T, Beller E, Heritier S, Hawley C, et al.Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology 2009;10:1. [MEDLINE: ] - PMC - PubMed
    1. Irish A, Viecelli A, Hawley C, Hooi L, Pascoe E, Paul-Brent P, et al.Effect of fish oil and aspirin on arteriovenous fistula failure in haemodialysis-a randomized controlled trial [abstract]. Nephrology 2016;21(Suppl 2):47. [EMBASE: 612312804]
    1. Irish A, FAVOURED Study Group.High rate of screening failure in the FAVOURED study [abstract no: 169]. Nephrology 2009;14(Suppl 1):A45. [CENTRAL: CN-00756870]
    1. Irish A.Baseline characteristics of the patients participating in the FAVOURED trial [abstract no: 009]. Nephrology 2014;19(Suppl 4):19. [EMBASE: 71587790]
Fiskerstrand 1985 {published data only}
    1. Fiskerstrand CE, Thompson IW, Burnet ME, Williams P, Anderton JL.Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis. Artificial Organs 1985;9(1):61-3. [MEDLINE: ] - PubMed
Frascà 1986 {published data only}
    1. Bonomini V, Vangelista A, Stefoni S, Scolari MP, Frascà GM, Raimondi C.Use of defibrotide in renal transplantation in man. Haemostasis 1986;16 Suppl 1:48-50. [MEDLINE: ] - PubMed
    1. Frascà GM, Vangelista A, Raimondi C, Bonomini V.Prevention of vascular graft lesions in renal transplant recipients with a new antithrombotic agent (defibrotide): a controlled study. Life Support Systems 1986;4(3):231-7. [MEDLINE: ] - PubMed
Frascà 1997 {published data only}
    1. Frascà GM, Cianciolo G.A clinical trial with defibrotide in IgA nephritis (IgA-GN) with impaired renal function [abstract]. Nephrology Dialysis Transplantation 1995;10(6):968. [CENTRAL: CN-00261099]
    1. Frascà GM, Martello M, Canova C, Isola E, Vangelista A, Bonomini V.Defibrotide treatment and disease progression in patients with IgA nephropathy and impaired renal function at diagnosis. Clinical Drug Investigation 1997;13(4):185-91. [EMBASE: 27192802]
    1. Frascà GM, Martello M, Sestigiani E, Canova C, Vangelista A, Bonomini V.Effects of defibrotide treatment in patients with IgA nephropathy and reduced renal function. Nephrology Dialysis Transplantation 1996;11(2):392-3. [MEDLINE: ] - PubMed
Gaede 2003 {published data only}
    1. Gaede P, Hansen HP, Parving HH, Pedersen O.Impact of low-dose acetylsalicylic acid on kidney function in type 2 diabetic patients with elevated urinary albumin excretion rate. Nephrology Dialysis Transplantation 2003;18(3):539-42. [MEDLINE: ] - PubMed
    1. Gaede P, Parving H, Pedersen O.Lack of impact of low-dose acetylsalisyic acid (ASA) on albuminuria in type 2 diabetic patients [abstract no: A0660]. Journal of the American Society of Nephrology 1999;10(Program & Abstracts):128A. [CENTRAL: CN-00583369]
Ghorbani 2009 {published data only}
    1. Ghorbani A, Aalamshah M, Shahbazian H, Ehsanpour A, Aref A.Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients. Indian Journal of Nephrology 2009;19(2):57-61. [MEDLINE: ] - PMC - PubMed
Ghorbani 2013 {published data only}
    1. Ghorbani A, Jasemi-Zergani F.Ticlopidine to prevent primary arteriovenous fistula failure in hemodialysis patients; a randomized controlled trial. Journal of Renal Injury Prevention 2013;2(3):109-11. [MEDLINE: ] - PMC - PubMed
Giustina 1998 {published data only}
    1. Giustina A, Perini P, Desenzani P, Bossoni S, Ianniello P, Milani M, et al.Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. Diabetes 1998;47(3):423-30. [MEDLINE: ] - PubMed
GLOBAL LEADERS 2018 {published data only}
    1. Gao C, Tomaniak M, Takahashi K, Kawashima H, Wang R, Hara H, et al.Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. Cardiovascular Diabetology 2020;19(1):179. [MEDLINE: ] - PMC - PubMed
    1. Tomaniak M, Chichareon P, Klimczak-Tomaniak D, Takahashi K, Kogame N, Modolo R, et al.Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial. Clinical Research in Cardiology 2020;109(7):930-43. [MEDLINE: ] - PubMed
    1. Vranckx P, Valgimigli M, Juni P, Hamm C, Steg PG, Heg D, et al.Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet 2018;392(10151):940-9. [MEDLINE: ] - PubMed
Goicoechea 2012 {published data only}
    1. Morales AM, Goicoechea M, Verde E, Carbayo J, Barbieri D, Delgado A, et al.Pentoxifylline, progression of chronic kidney disease (CKD) and cardiovascular mortality: long-term follow-up of a randomized clinical trial. Journal of Nephrology 2019;32(4):581-7. [MEDLINE: ] - PubMed
    1. Goicoechea M, Garcia de Vinuesa S, Quiroga B, Verdalles U, Barraca D, Yuste C, et al.Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial. Journal of Nephrology 2012;25(6):969-75. [MEDLINE: ] - PubMed
Gonzalez 1995 {published data only}
    1. Gonzalez MT, Castelao AM, Valles M, Cruzado JM, Mauri JM.Platelet antiaggregants (PA) could decrease the rate of progression of chronic renal failure (CRF) in diabetic patients (DP) treated previously with angiotensin converting enzyme inhibitors (ACEi) [abstract]. In: ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:200. [CENTRAL: CN-00509215]
Gröntoft 1985 {published data only}
    1. Gröntoft KC, Mulec H, Gutierrez A, Olander R.Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis. Scandinavian Journal of Urology & Nephrology 1985;19(1):55-7. [MEDLINE: ] - PubMed
Gröntoft 1998 {published data only}
    1. Gröntoft K, Larsson R, Mulec H, Weiss LG, Dickinson JP.Ticlopidine in fistula surgery: double-blind comparison against placebo on the rate of early occlusion of arterio-venous fistulae [abstract]. In: 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel. 1993:398. [CENTRAL: CN-00601921]
    1. Gröntoft KC, Larsson R, Mulec H, Weiss LG, Dickinson JP.Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group. Scandinavian Journal of Urology & Nephrology 1998;32(4):276-83. [MEDLINE: ] - PubMed
Guo 1998 {published data only}
    1. Guo Z, Hasbach J, Koschinsky T.Effect of acetylsalicylic acid on renal function of Type 1 diabetic patients with microalbuminuria [Wirkung von Azetylsalizylsaure auf die Nierenfunktion bei Typ-1- Diabetikern mit Mikroalbuminurie. Placebokontrollierte Crossover-Pilotstudie]. Diabetes und Stoffwechsel 1998;7(2):41-7. [EMBASE: 28146337]
Hansen 2000 {published data only}
    1. Hansen HP, Gaede PH, Jensen BR, Parving HH.Lack of impact of low-dose acetylsalicylic acid on kidney function in type 1 diabetic patients with microalbuminuria. Diabetes Care 2000;23(12):1742-5. [MEDLINE: ] - PubMed
Harter 1979 {published data only}
    1. Harter HR, Burch JW, Majerus PW, Stanford N, Delmez JA, Anderson CB, et al.Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. New England Journal of Medicine 1979;301(11):577-9. [MEDLINE: ] - PubMed
Hidaka 2013 {published data only}
    1. Hidaka S, Kobayashi S, Iwagami M, Isshiki R, Tsutsumi D, Mochida Y, et al.Sarpogrelate hydrochloride, a selective 5-HT(2A) receptor antagonist, improves skin perfusion pressure of the lower extremities in hemodialysis patients with peripheral arterial disease. Renal Failure 2013;35(1):43-8. [MEDLINE: ] - PubMed
HOT 1993 {published and unpublished data}
    1. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al.Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351(9118):1755-62. [MEDLINE: ] - PubMed
    1. Hansson L, Zanchetti A.The Hypertension Optimal Treatment (HOT) Study: 24-month data on blood pressure and tolerability. Blood Pressure 1997;6(5):313-7. [MEDLINE: ] - PubMed
    1. Hansson L, Zanchetti A.The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results. Blood Pressure 1994;3(5):322-7. [MEDLINE: ] - PubMed
    1. Hansson L.The Hypertension Optimal Treatment study and the importance of lowering blood pressure. Journal of Hypertension - Supplement 1999;17(1):S9-13. [MEDLINE: ] - PubMed
    1. Jardine M, Ninomiya T, Cass A, Turnbull F, Gallagher M, Zoungas S, et al.Aspirin benefit increases as eGFR declines: results from a randomised controlled trial in a hypertensive population [abstract no: 086]. Nephrology 2010;15(Suppl 4):49. [EMBASE: 70467090]
IMPACT II 1997 {unpublished data only}
    1. Blankenship JC, Sigmon KN, Pieper KS, O'Shea C, Tardiff BE, Tcheng JE, et al.Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT--(Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) II Trial. American Journal of Cardiology 2001;88(9):969-73. [MEDLINE: ] - PubMed
    1. Gilchrist IC, Gardner LH, Muhlestein JB, Arnold AM, Lincoff AM, Califf RM, et al.Effect of institutional volume and academic status on outcomes of coronary interventions: the IMPACT-II experience. American Heart Journal 1999;138(5 Pt 1):976-82. [MEDLINE: ] - PubMed
    1. Mandak JS, Blankenship JC, Gardner LH, Berkowitz SD, Aguirre FV, Sigmon KN, et al.Modifiable risk factors for vascular access site complications in the IMPACT II trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Journal of the American College of Cardiology 1998;31(7):1518-24. [MEDLINE: ] - PubMed
    1. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997;349(9063):1422-8. [MEDLINE: ] - PubMed
    1. Tardiff BE, Califf RM, Tcheng JE, Lincoff AM, Sigmon KN, Harrington RA, et al.Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II. Journal of the American College of Cardiology 1999;33(1):88-96. [MEDLINE: ] - PubMed
Jiao 2013 {published data only}
    1. Jiao XM, Jiao XJ, Zhang XG, Xu XP, Wu JX, Yao L, et al.Cilostazol reduces microalbuminuria in type 2 diabetic nephropathy. Chinese Medical Journal 2013;126(22):4395-6. [MEDLINE: ] - PubMed
JPAD 2008 {published data only}
    1. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al.Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.[Erratum in: JAMA. 2009 May 13;301(18):1882], [Erratum in: JAMA. 2012 Nov 14;308(18):1861]. JAMA 2008;300(18):2134-41. [MEDLINE: ] - PubMed
    1. Okada S, Morimoto T, Ogawa H, Sakuma M, Soejima H, Nakayama M, et al.Effect of low-dose aspirin on primary prevention of cardiovascular events in Japanese diabetic patients at high risk. Circulation Journal 2013;77(12):3023-8. [MEDLINE: ] - PubMed
    1. Okada S, Morimoto T, Ogawa H, Sakuma M, Soejima H, Nakayama M, et al.Is long-term low-dose aspirin therapy associated with renal dysfunction in patients with type 2 diabetes? JPAD2 cohort study. PLoS ONE [Electronic Resource] 2016;11(1):e0147635. [MEDLINE: ] - PMC - PubMed
    1. Okada S, Morimoto T, Ogawa H, Sakuma M, Soejima H, Ohtorii M, et al.Long-term use of low-dose aspirin develops proteinuria in patients with diabetes: A reanalysis of JPAD study [abstract no: 10863]. Circulation 2013;128(22 Suppl 1). [EMBASE: 71337722]
    1. Saito Y, Morimoto T, Ogawa H, Nakayama M, Uemura S, Doi N, et al.Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. Diabetes Care 2011;34(2):280-5. [MEDLINE: ] - PMC - PubMed
J‐PADD 2014 {published data only}
    1. Ohtake T, Sato M, Nakazawa R, Kondoh M, Kobayashi S.Effect of beraprost sodium (PGI2 analogue) on peripheral arterial disease (PAD) in patients on hemodialysis: result from a multicenter randomized prospective interventional study [abstract no: Su528]. NDT Plus 2010;3(Suppl 3):iii487. [EMBASE: 70484748]
    1. Ohtake T, Sato M, Nakazawa R, Kondoh M, Miyaji T, Moriya H, et al.Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients. Therapeutic Apheresis & Dialysis 2014;18(1):1-8. [MEDLINE: ] - PubMed
Kaegi 1974 {published data only}
    1. Kaegi A, Pineo GF, Shimizu A, Trivedi H, Hirsh J, Gent M.Arteriovenous-shunt thrombosis. Prevention by sulfinpyrazone. New England Journal of Medicine 1974;290(6):304-6. [MEDLINE: ] - PubMed
    1. Kaegi A, Pineo GF, Shimizu A, Trivedi H, Hirsh J, Gent M.The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis. Circulation 1975;52(3):497-9. [MEDLINE: ] - PubMed
Kamper 1997 {published data only}
    1. Kamper AM, Lins RL, Zachee P, Van Bergen S, Hosten S, Daelemans R.Safety of combining ticlopidine with nadroparin in the routine treatment of chronic hemodialysis patients. Nephron 1997;77(4):484-5. [MEDLINE: ] - PubMed
Kauffmann 1980 {published data only}
    1. Kauffmann HM, Adams MB, Hebert LA, Walczak PM.Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings 1980;12(2):311-4. [MEDLINE: 6771905 ] - PubMed
Kaufman 2003 {published and unpublished data}
    1. Chang JJ, Concato J, Wells CK, Crowley ST.Impact of adherence to clinical guidelines on mortality in hemodialysis patients [abstract no: SA-PO384]. Journal of the American Society of Nephrology 2004;15(Oct):386A. [CENTRAL: CN-00583156]
    1. Kaufman JS, O'Connor TZ, Zhang JH, Cronin RE, Fiore LD, Ganz MB, et al.Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. Journal of the American Society of Nephrology 2003;14(9):2313-21. [MEDLINE: ] - PubMed
    1. Kaufman JS, O’Connor TZ, Zhang JH, Cronin RE, Fiore LD, Ganz MB, et al.Combination aspirin plus clopidogrel in the prevention of hemodialysis access graft thrombosis [abstract no: A1495]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):291A. - PubMed
Khajehdehi 2002 {published data only}
    1. Khajehdehi P, Roozbeh J, Mostafavi H.A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy. Scandinavian Journal of Urology & Nephrology 2002;36(2):145-8. [MEDLINE: ] - PubMed
Kobayashi 1980 {published data only}
    1. Kobayashi K, Maeda K, Koshikawa S, Kawaguchi Y, Shimizu N, Naito C.Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis: a multicenter collaborative double blind study. Thrombosis Research 1980;20(2):255-61. [MEDLINE: ] - PubMed
Kontessis 1993 {published data only}
    1. Kontessis PS, Jones SL, Barrow SE, Stratton PD, Alessandrini P, De Cosmo S, et al.Effect of selective inhibition of thromboxane synthesis on renal function in diabetic nephropathy. Journal of Laboratory & Clinical Medicine 1993;121(3):415-23. [MEDLINE: ] - PubMed
Kooistra 1994 {published data only}
    1. Kooistra MP, Es A, Marx JJ, Hertsig M, Struyvenberg A.Effects of low dose aspirin on thrombovascular accidents during treatment with rHuEpo: a multicentre, controlled, cross-over study [abstract]. Nephrology Dialysis Transplantation 1993;8:277. [CENTRAL: CN-00260772] - PubMed
    1. Kooistra MP, Es A, Marx JJ, Hertsig ML, Struyvenberg A.Low-dose aspirin does not prevent thrombovascular accidents in low-risk haemodialysis patients during treatment with recombinant human erythropoietin. Nephrology Dialysis Transplantation 1994;9(8):1115-20. [MEDLINE: ] - PubMed
Koyama 1990 {published data only}
    1. Koyama A, Narita M, Tojo S.Therapeutic effects of dipyridamole on primary glomerulonephritis [abstract]. In: 11th International Congress of Nephrology; 1990 Jul 15-20; Tokyo, Japan. 1990:12. [CENTRAL: CN-00446186]
Liang 2015 {published data only}
    1. Liang J, Wang Z, Shi D, Liu Y, Zhao Y, Han H, et al.High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention. Angiology 2015;66(4):319-25. [MEDLINE: ] - PubMed
Michie 1977 {published data only}
    1. Michie DD, Wombolt DG.Use of sulfinpyrazone to prevent thrombus formation in arteriovenous fistulas and bovine grafts of patients on chronic hemodialysis. Current Therapeutic Research - Clinical & Experimental 1977;22(1 II):196-204. [EMBASE: 8152617]
Middleton 1992 {published data only}
    1. Middleton DA, Deichsel G.The prophylaxis of thrombosis in new arteriovenous dialysis shunts in the arm by low-dose acetylsalicylic acid and dipyridamole. Boehringer Ingelheim. Internal report 1992.
Milutinovic 1993 {published data only}
    1. Milutinovic S, Gasparovic V, Milutinovic E, Buturovic-Ponikvar J.Ticlopidine improves dialysis clearance of solutes in uremic patients by reducing blood clotting in dialyser fibers. International Journal of Artificial Organs 1993;16(5):249-52. [MEDLINE: ] - PubMed
Movchan 2001 {published data only}
    1. Movchan EA, Chuprova AV, Tov NL, Vol'vich NV.Desaggregation therapy of acute glomerulonephritis [Dezagregatsionnaia terapiia ostrogo glomerulonefrita]. Klinicheskaia Meditsina 2001;79(12):44-7. [MEDLINE: ] - PubMed
Mozafar 2013 {published data only}
    1. Mozafar M, Samsami M, Sobhiyeh MR, Jabbehdari S, Fallah ZM.Effectiveness of aspirin on double lumen permanent catheter efficacy in ESRD. Nephrourology Monthly 2013;5(2):762-5. [MEDLINE: ] - PMC - PubMed
Mozafar 2018 {published data only}
    1. Mozafar M, Alborzi M, Moradi A.Effects of clopidogrel on longevity of permanent double-lumen catheter patency in dialysis patients: A single-blind placebo-controlled clinical trial. Nephro-Urology Monthly 2018;10(2):e58135. [EMBASE: 622226387]
Nakamura 2001d {published data only}
    1. Nakamura T, Ushiyama C, Takahashi Y, Tanaka A, Shimada N, Ebihara I, et al.Effect of dilazep dihydrochloride on urinary albumin excretion in patients with autosomal dominant polycystic kidney disease. Nephron 2001;88(1):80-2. [MEDLINE: ] - PubMed
Nakamura 2002b {published data only}
    1. Nakamura T, Ushiyama C, Osada S, Ugai K, Takahashi Y, Tanaka A, et al.Effect of dilazep dihydrochloride on serum cardiac troponin T levels in hemodialysis patients. Kidney & Blood Pressure Research 2002;25(1):50-4. [MEDLINE: ] - PubMed
NCT01252056 {published data only}
    1. Guo X.A clinical study to evaluate the efficacy and safety of cilostazol and probucol in combination on patients with diabetic nephropathy. www.clinicaltrials.gov/show/nct01252056 (first received 2 December 2010).
Nyberg 1984 {published data only}
    1. Nyberg G, Larsson O, Westberg NG, Aurell M, Jagenburg R, Blohme G.A platelet aggregation inhibitor--ticlopidine--in diabetic nephropathy: a randomized double blind study. Clinical Nephrology 1984;21(3):184-7. [MEDLINE: ] - PubMed
Ogawa 2008 {published data only}
    1. Ogawa S, Mori T, Nako K, Ishizuka T, Ito S.Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. Clinical Journal of the American Society of Nephrology: CJASN 2008;3(2):362-8. [MEDLINE: ] - PMC - PubMed
OPT‐CKD 2018 {published data only}
    1. Han Y.Comparison of the pharmacodynamics and pharmacokinetics of ticagrelor versus clopidogrel in patients with chronic kidney disease and non-ST-elevation acute coronary syndromes (OPT-CKD trial) [abstract no: TCT-483]. Journal of the American College of Cardiology 2017;70(18 Suppl 1):B200. [EMBASE: 619771602]
    1. Wang H, Qi J, Li Y, Tang Y, Li C, Li J, et al.Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. British Journal of Clinical Pharmacology 2018;84(1):88-96. [MEDLINE: ] - PMC - PubMed
Ota 1996 {published data only}
    1. Ota K, Teraoka S, Akiwasa T, Mimura N, Hirasawa Y, Sakai T, et al.Clinical efficacy of E5510 (satigrel), an antiplatelet agent, for preventing blood clotting in the extracorporeal circuit during hemodialysis (3) - A double-blind comparison with ticlopidine hydrochloride. Rinsho Hyoka 1996;24(1):9-38.
PEGASUS‐TIMI 54 2014 {published data only}
    1. Bonaca MP, Bhatt DL, Braunwald E, Cohen M, Steg PG, Storey RF, et al.Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. American Heart Journal 2014;167(4):437-44. [MEDLINE: ] - PubMed
    1. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al.Long-term use of ticagrelor in patients with prior myocardial infarction. New England Journal of Medicine 2015;372(19):1791-800. [MEDLINE: ] - PubMed
    1. Bonaca MP, Goto S, Bhatt DL, Steg PG, Storey RF, Cohen M, et al.Prevention of stroke with ticagrelor in patients with prior myocardial infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). Circulation 2016;134(12):861-71. [MEDLINE: ] - PubMed
    1. Dellborg M, Bonaca MP, Storey RF, Steg PG, Im KA, Cohen M, et al.Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: Insights from PEGASUS-TIMI 54 [abstract]. European Heart Journal 2017;38(Suppl 1):794-5. [EMBASE: 621235545] - PMC - PubMed
    1. Lozano I, Rondan J, Vegas JM, Segovia E.Cost-effectiveness of long-term ticagrelor in patients with prior myocardial infarction: analysis by subgroups. Journal of the American College of Cardiology 2018;71(1):107-8. [MEDLINE: ] - PubMed
PIANO‐2 CKD 2011 {published data only}
    1. Kim W, Kang WY, Woo JS.Objectives: The purpose of this study was to determine the functional impact of cilostazol in patients with chronic kidney disease (CKD) undergoing hemodialysis [abstract no: TCT-497]. Journal of the American College of Cardiology 2011;58(20 Suppl 1):B135. [EMBASE: 70581866]
    1. Woo JS, Kim W, Ha SJ, Jeong KH, Lee TW, Ihm CG, et al.A comparison of clopidogrel responsiveness in patients with chronic renal failure: results of the adjunctive cilostazol versus high maintenance dose clopidogrel (PIANO) study [abstract no: AS-252]. American Journal of Cardiology 2011;107(8 Suppl 1):100-1A. [EMBASE: 70401953]
    1. Woo JS, Kim W, Lee SR, Jung KH, Kim WS, Lew JH, et al.Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney disease (PIANO-2 CKD) randomized study. American Heart Journal 2011;162(6):1018-25. [MEDLINE: ] - PubMed
PIANO‐3 2015 {published data only}
    1. Jeong KH, Cho JH, Woo JS, Kim JB, Kim WS, Lee TW, et al.Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study. American Journal of Kidney Diseases 2015;65(6):916-24. [MEDLINE: ] - PubMed
    1. Jeong KH, Lee TW, Kim JS, Lee SY, Lee SH, Moon JY, et al.Platelet reactivity in patients with end stage renal disease receiving clopidogrel compared with ticagrelor: a randomized crossover study [abstract no: FP610]. Nephrology Dialysis Transplantation 2015;30(Suppl 3):iii276. [EMBASE: 72207028]
    1. Woo JS, Kim W, Kim HS, Hwang SJ, Kim JB, Kim SJ, et al.Randomized assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with chronic kidney disease performing hemodialysis [abstract]. European Heart Journal 2014;35(Suppl 1):7-8. [EMBASE: 71646762]
PIANO‐6 2017 {published data only}
    1. Kim JS, Lee TW, Ihm C, Lee SH, Kim SY, Lee SY, et al.Relationship of ticagrelor dose and platelet reactivity in patients with end stage renal disease on hemodialysis [abstract no: FR-PO727]. Journal of the American Society of Nephrology 2015;26(Abstract Suppl):529A.
    1. Kim JS, Woo JS, Kim JB, Kim WS, Lee TW, Kim KS, et al.The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis. International Journal of Cardiology 2017;238:110-6. [MEDLINE: ] - PubMed
    1. Kim W, Woo JS, Kim WS, Kim JB, Kim HO, Kim JM.Pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis [abstract]. European Heart Journal 2016;37(Suppl 1):636. [EMBASE: 612284362]
Pierucci 1989 {published data only}
    1. Pierucci A, Simonetti BM, Pecci G, Feriozzi S, Mavrikakis G, Cinotti GA, et al.Low dose aspirin in patients with lupus nephritis [abstract]. Kidney International 1988;33(1):281. [CENTRAL: CN-00583819]
    1. Pierucci A, Simonetti BM, Pecci G, Mavrikakis G, Feriozzi S, Cinotti GA, et al.Acute effects of a thromboxane receptor antagonist on renal function in patients with lupus nephritis [abstract]. Kidney International 1987;31(1):283. [CENTRAL: CN-00724956]
    1. Pierucci A, Simonetti BM, Pecci G, Mavrikakis G, Feriozzi S, Cinotti GA, et al.Improvement of renal function with selective thromboxane antagonism in lupus nephritis. New England Journal of Medicine 1989;320(7):421-5. [MEDLINE: ] - PubMed
PLATO 2009 {published data only}
    1. Akerblom A, Wallentin L, Larsson A, Siegbahn A, Becker RC, Budaj A, et al.Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet Inhibition and Patient Outcomes (PLATO) study. Clinical Chemistry 2013;59(9):1369-75. [MEDLINE: ] - PubMed
    1. Akerblom A, Wallentin L, Siegbahn A, Becker RC, Budaj A, Horrow J, et al.Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study. American Heart Journal 2012;164(5):728-34. [MEDLINE: ] - PubMed
    1. Andell P, James SK, Cannon CP, Cyr DD, Himmelmann A, Husted S, et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: an analysis from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Journal of the American Heart Association 2015;4(10):e002490. [MEDLINE: ] - PMC - PubMed
    1. Armstrong PW, Siha H, Fu Y, Westerhout CM, Steg PG, James SK, et al.ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy. Circulation 2012;125(3):514-21. [MEDLINE: ] - PubMed
    1. Armstrong PW, Westerhout CM, Fu Y, Harrington RA, Storey RF, Katus H, et al.Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy. American Journal of Medicine 2013;126(8):723-9. [MEDLINE: ] - PubMed
PREDIAN 2011 {published data only}
    1. Navarro-Gonzalez JF, Sanchez-Nino MD, Donate-Correa J, Martin-Nunez E, Ferri C, Perez-Delgado N, et al.Effects of pentoxifylline on soluble klotho concentrations and renal tubular cell expression in diabetic kidney disease. Diabetes Care 2018;41(8):1817-20. [MEDLINE: ] - PubMed
PRISM‐PLUS 1998 {published data only (unpublished sought but not used)}
    1. Huynh T, Nasmith J, Luong TM, Bernier M, Pharand C, Xue-Qiao Z, et al.Complementary prognostic values of ST segment deviation and Thrombolysis In Myocardial Infarction (TIMI) risk score in non-ST elevation acute coronary syndromes: insights from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Canadian Journal of Cardiology 2009 Dec;25(12):e417-21. [MEDLINE: ] - PMC - PubMed
    1. Huynh T, Piazza N, DiBattiste PM, Snapinn SM, Wan Y, Pharand C, et al.Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS study. International Journal of Cardiology 2005;100(1):73-8. [MEDLINE: ] - PubMed
    1. Huynh T, Theroux P, Snapinn S, Wan Y, PRISM-PLUS Investigators.Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study). American Heart Journal 2003;146(4):668-73. [MEDLINE: ] - PubMed
    1. Januzzi JL Jr, Snapinn SM, DiBattiste PM, Jang IK, Theroux P.Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Circulation 2002;105(20):2361-6. [MEDLINE: ] - PubMed
    1. Mega JL, Morrow DA, Sabatine MS, Zhao XQ, Snapinn SM, DiBattiste PM, et al.Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. American Heart Journal 2005;149(5):846-50. [MEDLINE: ] - PubMed
PURSUIT 1997 {unpublished data only}
    1. Akkerhuis KM, Deckers JW, Boersma E, Harrington RA, Stepinska J, Mahaffey KW, et al.Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT. European Heart Journal 2000;21(5):371-81. [MEDLINE: ] - PubMed
    1. Akkerhuis KM, Maas AC, Klootwijk PA, Krucoff MW, Meij S, Califf RM, et al.Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: relation with death and myocardial infarction. PURSUIT ECG-Ischemia Monitoring Substudy Investigators. Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. Journal of Electrocardiology 2000;33(2):127-36. [MEDLINE: ] - PubMed
    1. Alexander JH, Harrington RA, Tuttle RH, Berdan LG, Lincoff AM, Deckers JW, et al.Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. American Journal of Cardiology 1999;83(8):1147-51. [MEDLINE: ] - PubMed
    1. Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, et al.Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation 2000;101(22):2557-67. [MEDLINE: ] - PubMed
    1. Brown RE, Henderson RA, Koster D, Hutton J, Simoons ML.Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using Integrilin Therapy. European Heart Journal 2002;23(1):50-8. [MEDLINE: ] - PubMed
Quarto Di Palo 1991 {published data only}
    1. Quarto Di Palo F, Elli A, Rivolta R, Parenti M, Palazzi P, Zanussi C.Prevention of chronic cyclosporine nephrotoxicity in renal transplantation by picotamide. Transplantation Proceedings 1991;23(1 Pt 2):969-71. [MEDLINE: ] - PubMed
RAPPORT 1998 {published and unpublished data}
    1. Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, et al.Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998;98(8):734-41. [MEDLINE: ] - PubMed
    1. Brener SJ, Barr LA, Burchenal JE, Wolski KE, Effron MB, Topol EJ.Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. RAPPORT investigators. ReoPro And Primary PTCA Organization and Randomized Trial. American Journal of Cardiology 1999;84(6):728-30. [MEDLINE: ] - PubMed
Reams 1985 {published data only}
    1. Reams GP, Young M, Sorkin M, Twardowski Z, Gloor H, Moore H, et al.Effects of dipyridamole on peritoneal clearances. Uremia Investigation 1985;9(1):27-33. [MEDLINE: ] - PubMed
RESIST 2008 {published data only}
    1. Cooper CJ, Haller ST, Colyer W, Steffes M, Burket MW, Thomas WJ, et al.Embolic protection and platelet inhibition during renal artery stenting. Circulation 2008;117(21):2752-60. [MEDLINE: ] - PubMed
    1. He W, Che J, Zhan D, Dawso T, Kanjwa S, Halle S, et al.Time dependant changes in systolic blood pressure after renal artery stenting: role of stenosis severity [abstract no: 14283]. Circulation 2012;126(21 Suppl 1). [EMBASE: 70958797]
    1. Kanjwal K, Cooper CJ, Virmani R, Haller S, Shapiro JI, Burket MW, et al.Predictors of embolization during protected renal artery angioplasty and stenting: Role of antiplatelet therapy. Catheterization & Cardiovascular Interventions 2010;76(1):16-23. [MEDLINE: ] - PubMed
    1. Kanjwal K, Haller S, Steffes M, Virmani R, Shapiro JI, Burket MW, et al.Complete versus partial distal embolic protection during renal artery stenting. Catheterization & Cardiovascular Interventions 2009;73(6):725-30. [MEDLINE: ] - PubMed
    1. Tian J, Haller S, Periyasamy S, Brewster P, Zhang H, Adlakha S, et al.Renal ischemia regulates marinobufagenin release in humans. Hypertension 2010;56(5):914-9. [MEDLINE: ] - PMC - PubMed
Rouzrokh 2010 {published data only}
    1. Rouzrokh M, Abbasi MR, Mirshemirani AR, Sobhiyeh MR.The effect of antiplatelet drugs on the patency rate of arterio-venous fistulae in hemodialysis patients. Iranian Journal of Pharmaceutical Research 2010;9(4):451-7. [EMBASE: 2011024056] - PMC - PubMed
Rubin 1982 {published data only}
    1. Rubin J, Adair C, Barnes T, Bower JD.Augmentation of peritoneal clearance by dipyridamole. Kidney International 1982;22(6):658-61. [MEDLINE: ] - PubMed
Salter 1984 {published data only}
    1. Salter MC, Crow MJ, Donaldson DR, Roberts TG, Rajah SM, Davison AM.Prevention of platelet deposition and thrombus formation on hemodialysis membranes: a double-blind randomized trial of aspirin and dipyridamole. Artificial Organs 1984;8(1):57-61. [MEDLINE: ] - PubMed
Schnepp 2000 {published data only}
    1. Schnepp M, Teichler S, Markau S, Rettkowski O, Priesack J, Deuber HJ, et al.Platelet function analysis during therapy with clopidogrel in endstage renal disease [abstract]. In: 37th Congress. European Renal Association. European Dialysis and Transplantation Association; 2000 Sept 17-20; Nice, France. 2000:191. [CENTRAL: CN-00461687]
Schulze 1990 {published data only}
    1. Schulze R, Langkopf B, Sziegoleit W.The effect of dipyridamole on the results of allogenic kidney transplantation [Der Einfluss von Dipyridamol auf die Ergebnisse der allogenen Nieren-transplantation]. Zeitschrift für Urologie und Nephrologie 1990;83(5):255-9. [MEDLINE: ] - PubMed
Sreedhara 1994 {published data only}
    1. Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM.Antiplatelet therapy in expanded polytetrafluoroethylene (EPTFE) graft thrombosis: results of a randomized double blind study [abstract no: 9P]. Journal of the American Society of Nephrology 1993;4(Program & Abstracts):388. [CENTRAL: CN-00485981]
    1. Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM.Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double blind study. Kidney International 1994;45(5):1477-83. [MEDLINE: ] - PubMed
Steiness 2018 {published data only}
    1. Steiness E, Brun N, Skarsfeldt T, Derwahl KM.Low dose anti-thromboxane reduces urinary albumin in patients with diabetic kidney disease [abstract no: SA-PO148]. Journal of the American Society of Nephrology 2018;29:773. [EMBASE: 633731990]
STOP 1995 {published and unpublished data}
    1. Mileti M, De Petri G, Bacchi M, Ogliari V, Pecchini F, Bufano G, et al.A trial to evaluate the efficacy of picotamide in preventing thrombotic occlusion of the vascular access in hemodialysis patients. Journal of Nephrology 1995;8(2):167-72. [EMBASE: 25209311]
Storck 1996 {published data only}
    1. Storck M, Schilling M, Mickley V, Techt B, Abendroth D.Influence of systemic cyclooxygenase inhibition with single-dose aspisol on kinetics of arachidonic acid metabolites in the venous effluate of transplanted kidney grafts in humans. Transplantation Proceedings 1996;28(1):312-3. [MEDLINE: ] - PubMed
Taber 1992 {published data only}
    1. Taber T, Maikranz P, Haag B, Dilley R, Gaylord G.Hemodialysis vascular graft stenosis may be altered by low-molecular weight dextran (LMD), but not by aspirin (ASA) [abstract]. Journal of the American Society of Nephrology 1992;3(3):397. [CENTRAL: CN-00858239]
Tang 2014 {published data only}
    1. Tang WH, Lin FH, Lee CH, Kuo FC, Hsieh CH, Hsiao FC, et al.Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial. Endocrine 2014;45(2):293-301. [MEDLINE: ] - PubMed
TARGET 2000 {published and unpublished data}
    1. Berger PB, Best PJ, Topol EJ, White J, DiBattiste PM, Chan AW, et al.The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. American Heart Journal 2005;149(5):869-75. [MEDLINE: ] - PubMed
    1. Kalyanasundaram A, Blankenship JC, Berger P, Herrmann H, McClure R, Moliterno D.Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: results from TARGET (do Tirofiban and ReoPro give similar efficacy trial?). Catheterization & Cardiovascular Interventions 2007;69(5):623-9. [MEDLINE: ] - PubMed
    1. Moliterno DJ, Topol EJ.A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study. American Heart Journal 2000;140(5):722-6. [MEDLINE: ] - PubMed
    1. Moliterno DJ, Yakubov SJ, DiBattiste PM, Herrmann HC, Stone GW, Macaya C, et al.Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Lancet 2002;360(9330):355-60. [MEDLINE: ] - PubMed
    1. Mukherjee D, Topol EJ, Bertrand ME, Kristensen SD, Herrmann HC, Neumann FJ, et al.Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up. European Heart Journal 2005;26(23):2524-8. [MEDLINE: ] - PubMed
Tayebi 2018 {published data only}
    1. Tayebi P, Kazemzadeh G, Banihashem A, Ravari H.Effect of low dose aspirin and dipyridamole on primary patency of arteriovenous grafts in hemodialysis patients: a randomized double-blind placebo-controlled trial. Electronic Physician [Electronic Resource] 2018;10(1):6135-9. [MEDLINE: ] - PMC - PubMed
Teng 2018 {published data only}
    1. Teng R, Muldowney S, Zhao Y, Berg JK, Lu J, Khan ND.Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. European Journal of Clinical Pharmacology 2018;74(9):1141-8. [MEDLINE: ] - PMC - PubMed
TRA 2P‐TIMI 50 2009 {published data only}
    1. Correa S, Bonaca MP, Scirica BM, Murphy SA, Goodrich EL, Morrow DA, et al.Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function. Journal of Thrombosis & Thrombolysis 2019;47(3):353-60. [MEDLINE: ] - PubMed
    1. Gaviria SC, Braunwald E, Bonaca MP, Murphy SA, Goodrich EL, Morrow DA, et al.The efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function: insights from the TRA 2P-TIMI 50 trial [abstract no: 15480]. Circulation 2017;136(Suppl 1). [EMBASE: 619986693]
    1. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, et al.Vorapaxar in the secondary prevention of atherothrombotic events. New England Journal of Medicine 2012;366(15):1404-13. [MEDLINE: ] - PubMed
    1. Morrow DA, Scirica BM, Fox KA, Berman G, Strony J, Veltri E, et al.Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. American Heart Journal 2009;158(3):335-41. [MEDLINE: ] - PubMed
TRACER 2013 {published data only}
    1. Cornel JH, Tricoci P, Horton J, Moliterno D, Wallentin L, Armstrong P, et al.Effects of glycoprotein IIB/IIIA inhibitors in combination with vorapaxar, a platelet thrombin-receptor antagonist, among patients with non-St-segment elevation acute coronary syndromes: insights from the TRACER trial [abstract]. Journal of the American College of Cardiology 2013;61(10 Suppl 1):E102. [EMBASE: 71019466] - PubMed
    1. Mahaffey KW, Pieper K, Vranckx P, Tricoci P, Van de Werf F, Held C, et al.Chronic kidney disease is associated with worse outcomes in ACS patients: results from the TRACER trial [abstract]. European Heart Journal 2014;35(Suppl 1):687. [EMBASE: 71649310]
TRITON‐TIMI 38 2006 {unpublished data only}
    1. Abaci A.The use of prasugrel in STEMI and NSTEMI: TRITON TIMI 38 study and subgroup analyses [Prasugrelin ST yukselmeli ve yukselmesiz miyokart enfarktusunde kullanimi: TRITON TIMI 38 caIismasi ve alt grup sonuclari]. Turk Kardiyoloji Dernegi Arsivi 2015;43 Suppl 2:1-6. [MEDLINE: ] - PubMed
    1. Antman EM, Wiviott SD, Murphy SA, Voitk J, Hasin Y, Widimsky P, et al.Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. Journal of the American College of Cardiology 2008;51(21):2028-33. [MEDLINE: ] - PubMed
    1. Bonaca MP, Wiviott SD, Braunwald E, Murphy SA, Ruff CT, Antman EM, et al.American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). Circulation 2012;125(4):577-83. [MEDLINE: ] - PubMed
    1. Capodanno D, Tamburino C.Cyphering the statistical and clinical significance of prasugrel in the TRITON-TIMI 38 trial. International Journal of Cardiology 2011;146(2):242-3. [MEDLINE: ] - PubMed
    1. Damman P, Winter RJ, Wallentin L, Fox KA.Letter by Damman et al regarding articles, "Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 Trials (FIR)" and "American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 Trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)". Circulation 2012;126(9):e136-7. [MEDLINE: ] - PubMed
UK‐HARP‐I 2005 {published and unpublished data}
    1. Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, et al.First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. American Journal of Kidney Diseases 2005;45(3):473-84. [MEDLINE: ] - PubMed
    1. Baigent C, UK-HARP Steering Committee.Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract no: SA-PO851]. Journal of the American Society of Nephrology 2002;13(Program & Abstracts):437A. [CENTRAL: CN-00444305]
Waseda 2016 {published data only}
    1. Waseda K, Saka Y, Takashima H, Kurita A, Ando H, Sakurai S, et al.Effect of CYP2C19 genotype on inhibition of platelet aggregation in hemodialysis patients with coronary artery disease [abstract]. Circulation 2016;134(Suppl 1):A14237. [EMBASE: 619219587]
Watanabe 2011b {published data only}
    1. Watanabe H, Nakagawa K, Kakihana M.Long-term effects of sarpogrelate, a selective serotonin receptor antagonist, in diabetic patients with stable angina and chronic kidney disease [abstract no: 11204]. Circulation 2011;124(21 Suppl 1). [EMBASE: 70620962]
Weseley 1982 {published data only}
    1. Weseley S, Goodman A.The effect of dipyridamole (Di) on the peritoneal dialysis (PD) clearance of creatinine and urea - a double-blind study [abstract]. Kidney International 1982;21(1):182.
Xydakis 2004 {published data only}
    1. Xydakis D, Papadagiannakis A, Sfakianaki M, Vakouti E, Papachristoforou K.The combination of clopidogrel (CL) and acetylsalicylic acid (ASA) inhibits more effective the platelet activation in haemodialysis patients with acute coronary syndromes (ACS) and high C reactive protein [abstract no: MP370]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:355. [CENTRAL: CN-00509568]
Yang 2016b {published data only}
    1. Yang MY, Han B, Xu Y, Tian LY, Zhang Y, Qiang YW.The effects of different dose of clopidogrel in elderly patients with unstable angina combining chronic kidney disease [abstract no: P12]. Journal of the American Geriatrics Society 2016;64(Suppl 2):S320. [EMBASE: 611887576]
Yuto 2012 {published data only}
    1. Yuto J, Ehara Y, Shibata K, Iwamoto T, Yasuda G, Yatsu K, et al.Effect of sarpogrelate on fistula patency of forearm arteriovenous anastomisis in uremic patients [abstract no: 276]. Kidney Research & Clinical Practice 2012;31(2):A86. [EMBASE: 70814985]
Zäuner 1994 {published data only}
    1. Zäuner I, Böhler J, Braun N, Grupp C, Heering P, Schollmeyer P.Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: a multicentre prospective clinical trial. Nephrology Dialysis Transplantation 1994;9(6):619-22. [MEDLINE: ] - PubMed

References to studies excluded from this review

AVERROES 2010 {published data only}
    1. Alexander W, Connolly S, Arnesen H.European Society of Cardiology: apixaban or aspirin in decreasing stroke risk (The AVERROES Trial) [abstract]. P and T 2010;35(10):580-1. [EMBASE: 359918604]
    1. Amin A, Deitelzweig S, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, et al.Comparison of medical costs of patients with atrial fibrillation unsuitable for warfarin treatment with apixaban or aspirin based on AVERROES trial. Clinical & Applied Thrombosis/Hemostasis 2015;21(3):235-40. [MEDLINE: ] - PubMed
    1. Bhagirath VC, Eikelboom JW, Hirsh J, Coppens M, Ginsberg J, Vanassche T, et al.Apixaban- calibrated anti-FXa activity in relation to outcome events and clinical characteristics in patients with atrial fibrillation: results from the AVERROES trial. TH Open 2017;1(2):e139-45. [EMBASE: 624302177] - PMC - PubMed
    1. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al.Apixaban in patients with atrial fibrillation. New England Journal of Medicine 2011;364(9):806-17. [MEDLINE: ] - PubMed
    1. Coppens M, Synhorst D, Eikelboom JW, Yusuf S, Shestakovska O, Connolly SJ.Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial. European Heart Journal 2014;35(28):1856-63. [MEDLINE: ] - PubMed
Bang 1994 {published data only}
    1. Bang BK, Yang CW, Kim YS, Chang YS, Yoon YS.Effect of combination therapy of captopril and dipyridamole on proteinuria in patients with IgA nephropathy [abstract]. Journal of the American Society of Nephrology 1994;5(3):346. [CENTRAL: CN-00550477]
Caravaca 1995a {published data only}
    1. Caravaca F, Lopez-Minguez JR, Arrobas M, Cubero J, Pizarro JL, Cid MC, et al.Haemodynamic changes induced by the correction of anaemia by erythropoietin: role of antiplatelet therapy. Nephrology Dialysis Transplantation 1995;10(9):1720-4. [MEDLINE: ] - PubMed
Changjiang 2015 {published data only}
    1. Changjiang H, Jian Q, Yuan Z, Liang Y, Puqing L, Xiaolong G.Tirofiban combined with fondaparinux for post-PCI treatment of patients with acute coronary syndrome and mild renal insufficiency. Cell Biochemistry & Biophysics 2015;73(3):603-7. [MEDLINE: ] - PubMed
Coli 2006 {published data only}
    1. Coli L, Donati G, Cianciolo G, Raimondi C, Comai G, Panicali L, et al.Anticoagulation therapy for the prevention of hemodialysis tunneled cuffed catheters (TCC) thrombosis. Journal of Vascular Access 2006;7(3):118-22. [MEDLINE: ] - PubMed
EXCITE 2000 {published data only}
    1. Brugts JJ, Mercado N, Hu S, Guarneri M, Price M, Schatz R, et al.Relation of periprocedural bleeding complications and long-term outcome in patients undergoing percutaneous coronary revascularization (from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] Trial). American Journal of Cardiology 2009;103(7):917-22. [MEDLINE: ] - PubMed
    1. Mercado N, Brugts JJ, Ix JH, Shlipak MG, Dixon SR, Gersh BJ, et al.Usefulness of proteinuria as a prognostic marker of mortality and cardiovascular events among patients undergoing percutaneous coronary intervention (data from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] trial). American Journal of Cardiology 2008;102(9):1151-5. [MEDLINE: ] - PubMed
    1. O'Neill WW, Serruys P, Knudtson M, Es GA, Timmis GC, Zwaan C, et al.Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. New England Journal of Medicine 2000;342(18):1316-24. [MEDLINE: ] - PubMed
Foroughinia 2017 {published data only}
    1. Foroughinia F, Foroozmehr M.Effect of pretreatment with omega-3 supplement on cardiac necrosis markers in chronic kidney disease patients undergoing elective percutaneous coronary intervention. Journal of Research in Pharmacy Practice 2017;6(2):94-9. [MEDLINE: ] - PMC - PubMed
    1. Foroughinia F, Movahed Nouri B, Kojuri J, Ostovan MA.Impact of omega-3 supplementation on high sensitive C-reactive protein level and 30-day major adverse cardiac events after the implementation of coronary stent in patients with chronic kidney disease: a randomized clinical study. Advanced Pharmaceutical Bulletin 2018;8(3):471-8. [MEDLINE: ] - PMC - PubMed
Gorter 1998 {published data only}
    1. Gorter JW.Preventive treatment of patients after non-disabling cerebral ischaemia of presumed arterial origin: Comparative randomized study with intensive anticoagulant therapy or aspirin treatment [Preventieve behandeling van patienten na niet-invaliderende cerebrale ischemie door vermoedelijk arteriele oorzaak: Vergelijkend, gerandomiseerd onderzoek met intensieve antistollingstherapie of behandeling met acetylsalicylzuur]. Nederlands Tijdschrift voor Geneeskunde 1998;142(6):306-12. [EMBASE: 28106209] - PubMed
Lee 1997 {published data only}
    1. Lee G, Choong HL, Chian GSC, Woo KT.Stabilisation of elevated serum creatinine (CR) in dipyridamole (DYP) and warfarin (WAR) treated patients with IgA nephropathy (IGAN): a three year controlled trial [abstract]. In: 9th Asian Colloquium in Nephrology; 1992 May 17-21; Seoul, Korea. 1992:106. [CENTRAL: CN-00461145]
    1. Lee GS, Choong HL, Chiang GS, Woo KT.Three-year randomized controlled trial of dipyridamole and low-dose warfarin in patients with IgA nephropathy and renal impairment. Nephrology 1997;3(1):117-21. [EMBASE: 27161092]
    1. Lee GS, Woo KT, Lim CH.Controlled trial of dipyridamole and low-dose warfarin in patients with IgA nephritis with renal impairment. Clinical Nephrology 1989;31:276. [CENTRAL: CN-00740470] - PubMed
Lindsay 1972 {published data only}
    1. Lindsay RM, Ferguson D, Prentice CR, Burton JA, McNicol GP.Reduction of thrombus formation on dialyser membranes by aspirin and RA 233. Lancet 1972;2(7790):1287-90. [MEDLINE: ] - PubMed
NITER 2005 {published data only}
    1. Scarpioni R, Michieletti E, Cristinelli L, Ugolotti U, Scolari F, Venturelli C, et al.Atherosclerotic renovascular disease: medical therapy versus medical therapy plus renal artery stenting in preventing renal failure progression: the rationale and study design of a prospective, multicenter and randomized trial (NITER). Journal of Nephrology 2005;18(4):423-8. [MEDLINE: ] - PubMed
    1. Scarpioni R, Michieletti E, Pavone L, Gandolfi S, Ricardi M, Pecchini P, et al.Atherosclerotic renovascular disease (ARVD): medical therapy plus renal artery stenting (PTRS), compared with medical therapy alone, do not offer more chances in preventing cardio-vascular (CV) or renal events, preliminary results of a prospective, multicenter and randomized trial [abstract no: M074]. In: World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009. [CENTRAL: CN-00841209]
    1. Siddiqui EU, Murphy TP, Naeem SS, Siddique A, McEnteggart GE, Scarpioni R.Interaction between albuminuria and treatment group outcomes for patients with renal artery stenosis: The NITER Study. Journal of Vascular & Interventional Radiology 2018;29(7):966-70. [MEDLINE: ] - PubMed
Perkovic 2004 {published data only}
    1. Perkovic V, Nicholls KM, Foreman A, Becker GJ.A randomised controlled trial of cardiovascular risk factor modification in end stage renal failure [abstract no: P62]. Nephrology 2004;9(Suppl 1):A16. [CENTRAL: CN-00509410]
    1. Perkovic V, Nicholls KM, Foreman A, Walker RG, Becker GJ.A randomised controlled trial of cardiovascular risk factor modification in end stage kidney disease [abstract no: SA-PO348]. Journal of the American Society of Nephrology 2004;15(Oct):377-8A. [CENTRAL: CN-00644351]
POISE‐2 2013 {published data only}
    1. Chludzinski A, Irani C, Mascha EJ, Kurz A, Devereaux PJ, Sessler DI.Protocol understanding and anxiety in perioperative clinical trial patients approached for consent on the day of surgery. Mayo Clinic Proceedings 2013;88(5):446-54. [MEDLINE: ] - PubMed
    1. Devereaux PJ, POISE-2 Investigators.Rationale and design of the PeriOperative ISchemic Evaluation-2 (POISE-2) trial: an international 2 x 2 factorial randomized controlled trial of acetyl-salicylic acid vs. placebo and clonidine vs. placebo in patients undergoing noncardiac surgery. American Heart Journal 2014;167(6):804-9. [MEDLINE: ] - PubMed
    1. Garg AX, Kurz A, Sessler DI, Cuerden M, Robinson A, Mrkobrada M, et al.Aspirin and clonidine in non-cardiac surgery: acute kidney injury substudy protocol of the Perioperative Ischaemic Evaluation (POISE) 2 randomised controlled trial. BMJ Open 2014;4(2):e004886. [MEDLINE: ] - PMC - PubMed
    1. Garg AX, Kurz A, Sessler DI, Cuerden M, Robinson A, Mrkobrada M, et al.Perioperative aspirin and clonidine and risk of acute kidney injury: a randomized clinical trial. JAMA 2014;312(21):2254-64. [MEDLINE: ] - PubMed
PRODIGY 2010 {published data only}
    1. Campo G, Punzetti S, Malagu M, Ferrari R, Valgimigli M.Two-year outcomes after first- or second-generation drug-eluting stent implantation in patients with in-stent restenosis. A PRODIGY trial substudy. International Journal of Cardiology 2014;173(2):343-5. [MEDLINE: ] - PubMed
    1. Campo G, Tebaldi M, Vranckx P, Biscaglia S, Tumscitz C, Ferrari R, et al.Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia). Journal of the American College of Cardiology 2014;63(6):506-12. [MEDLINE: ] - PubMed
    1. Costa F, Adamo M, Ariotti S, Ferrante G, Navarese EP, Leonardi S, et al.Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy duration. Eurointervention 2016;11(11):e1222-30. [MEDLINE: ] - PubMed
    1. Costa F, Vranckx P, Leonardi S, Moscarella E, Ando G, Calabro P, et al.Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial. European Heart Journal 2015;36(20):1242-51. [MEDLINE: ] - PubMed
    1. Crimi G, Leonardi S, Costa F, Adamo M, Ariotti S, Valgimigli M.Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer PRODIGY trial. International Journal of Cardiology 2016;212:110-7. [MEDLINE: ] - PubMed
RAS‐CAD 2009 {published data only}
    1. Marcantoni C, Zanoli L, Rastelli S, Tripepi G, Matalone M, Di Landro D, et al.Stenting of renal artery stenosis in coronary artery disease (RAS-CAD) study: a prospective, randomized trial. Journal of Nephrology 2009;22(1):13-6. [MEDLINE: ] - PubMed
    1. Marcantoni C, Zanoli L, Rastelli S, Tripepi G, Matalone M, Mangiafico S, et al.Effect of renal artery stenting on left ventricular mass: a randomized clinical trial. American Journal of Kidney Diseases 2012;60(1):39-46. [MEDLINE: ] - PubMed
REPLACE‐2 2003 {published data only}
    1. Blankenship JC, Haldis T, Feit F, Hu T, Kleiman NS, Topol EJ, et al.Angiographic adverse events, creatine kinase-MB elevation, and ischemic end points complicating percutaneous coronary intervention (a REPLACE-2 substudy). American Journal of Cardiology 2006;97(11):1591-6. [MEDLINE: ] - PubMed
    1. Chacko M, Lincoff AM, Wolski KE, Cohen DJ, Bittl JA, Lansky AJ, et al.Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial. American Heart Journal 2006;151(5):1032-7. [MEDLINE: ] - PubMed
    1. Chew DP, Lincoff AM, Gurm H, Wolski K, Cohen DJ, Henry T, et al.Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). American Journal of Cardiology 2005;95(5):581-5. [MEDLINE: ] - PubMed
    1. Cohen DJ, Lincoff AM, Lavelle TA, Chen HL, Bakhai A, Berezin RH, et al.Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. Journal of the American College of Cardiology 2004;44(9):1792-800. [MEDLINE: ] - PubMed
    1. Exaire JE, Butman SM, Ebrahimi R, Kleiman NS, Harrington RA, Schweiger MJ, et al.Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial. American Heart Journal 2006;152(1):157-63. [MEDLINE: ] - PubMed
Sakai 1991 {published data only}
    1. Sakai H, Watanabe S, Inoue I, Tanaka K, Yagame M, Machimura H, et al.Effect of urokinase on preservation of renal function in patients with diabetic nephropathy. Journal of Diabetic Complications 1991;5(2-3):95-7. [MEDLINE: ] - PubMed
SPS3 2018 {published data only}
    1. Ikeme JC, Pergola PE, Scherzer R, Shlipak MG, Benavente OR, Peralta CA.Post hoc analyses of randomized clinical trial for the effect of clopidogrel added to aspirin on kidney function. Clinical Journal of the American Society of Nephrology: CJASN 2017;12(7):1040-7. [MEDLINE: ] - PMC - PubMed
STENO‐2 1999 {published data only}
    1. Gaede P, Lund-Andersen H, Parving HH, Pedersen O.Effect of a multifactorial intervention on mortality in type 2 diabetes. New England Journal of Medicine 2008;358(6):580-91. [MEDLINE: ] - PubMed
    1. Gaede P, Parving H, Pedersen O.Multifactorial intervention in patients with type 2 diabetes: long-term effects on mortality and vascular complications [abstract no: SA-FC042]. Journal of the American Society of Nephrology 2007;18(Abstracts):43A. [CENTRAL: CN-00740461]
    1. Gaede P, Valentine WJ, Palmer AJ, Tucker DM, Lammert M, Parving HH, et al.Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. Diabetes Care 2008;31(8):1510-5. [MEDLINE: ] - PMC - PubMed
    1. Gaede P, Vedel P, Larsen N, Jensen G, Parving H, Pedersen O.The Steno-2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: 181]. In: 38th Annual Meeting of the European Association for the Study of Diabetes (EASD); 2002 Sept 1-5; Budapest, Hungary. 2002. [CENTRAL: CN-01912459]
    1. Gaede P, Vedel P, Larsen N, Jensen G, Parving HH, Pedersen O.The STENO-2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: F-FC031]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts):72A. [CENTRAL: CN-00445410]
Swan 1995a {published data only}
    1. Halstenson CE, Swan SK, Collins AJ, Ellefson J, Parr K, Blue J, et al.Pharmacologic profile of diaspirin crosslinked hemoglobin (DCLHB) in hemodialysis (HD) patients [abstract no: 84P]. Journal of the American Society of Nephrology 1994;5(3):451. [CENTRAL: CN-00583893]
    1. Swan SK, Halstenson CE, Collins AJ, Colburn WA, Blue J, Przybelski RJ.Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients. American Journal of Kidney Diseases 1995;26(6):918-23. [MEDLINE: ] - PubMed
    1. Swan SK, Halstenson CE, Collins AJ, Ellefson J, Parr K, Blue J, et al.Pharmacodynamic and pharmacokinetic parameters of diaspirin cross-linked hemoglobin (DCLHB) in hemodialysis (HD) patients [abstract]. In: ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain. 1995:559. [CENTRAL: CN-00509497]
TRILOGY ACS 2010 {published data only}
    1. Bakal JA, Roe MT, Ohman EM, Goodman SG, Fox KA, Zheng Y, et al.Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial. European Heart Journal 2015;36(6):385-92A. [MEDLINE: ] - PubMed
    1. Chin CT, Neely B, Magnus OE, Armstrong PW, Corbalan R, White HD, et al.Time-varying effects of prasugrel versus clopidogrel on the long-term risks of stroke after acute coronary syndromes: results from the TRILOGY ACS trial. Stroke 2016;47(4):1135-9. [MEDLINE: ] - PubMed
    1. Chin CT, Roe MT, Fox KA, Prabhakaran D, Marshall DA, Petitjean H, et al.Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. American Heart Journal 2010;160(1):16-22. [MEDLINE: ] - PubMed
    1. Cornel JH, Ohman EM, Neely B, Clemmensen P, Sritara P, Zamoryakhin D, et al.Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: insights from the TRILOGY ACS trial.[Erratum in: Am Heart J. 2014 Oct;168(4):605]. American Heart Journal 2014;168(1):76-87. [MEDLINE: ] - PubMed
    1. Cornel JH, Tricoci P, Horton J, Moliterno D, Wallentin L, Armstrong P, et al.Effects of glycoprotein IIB/IIIA inhibitors in combination with vorapaxar, a platelet thrombin-receptor antagonist, among patients with non-St-segment elevation acute coronary syndromes: Insights from the TRACER trial [abstract]. Journal of the American College of Cardiology 2013;61(10 Suppl 1):E102. [EMBASE: 71019466] - PubMed
Woo 1987 {published data only}
    1. Woo KT, Chiang GS, Lim CH.Follow-up renal biopsies in IgA nephritic patients on triple therapy. Clinical Nephrology 1987;28(6):304-5. [MEDLINE: ] - PubMed
    1. Woo KT, Chiang GS, Yap HK, Lim CH.Controlled therapeutic trial of IgA nephritis with follow-up renal biopsies. Annals of the Academy of Medicine, Singapore 1988;17(2):226-31. [MEDLINE: ] - PubMed
    1. Woo KT, Edmondson RP, Yap HK, Wu AY, Chiang GS, Lee EJ, et al.Effects of triple therapy on the progression of mesangial proliferative glomerulonephritis. Clinical Nephrology 1987;27(2):56-64. [MEDLINE: ] - PubMed
    1. Woo KT, Lee GS, Lau YK, Chiang GS, Lim CH.Effects of triple therapy in IgA nephritis: a follow-up study 5 years later. Clinical Nephrology 1991;36(2):60-6. [MEDLINE: ] - PubMed
    1. Woo KT, Lee GSL, Lau YK, Chiang GSC, Lim CH.Anti platelet therapy in IgA nephritis [abstract]. In: 11th International Congress of Nephrology; 1990 Jul 15-20; Tokyo, Japan. 1990:13. [CENTRAL: CN-00448412]
Wu 2018a {published data only}
    1. Wu HB, Tian HP, Wang XC, Bai SR, Li XN, Zhang LN, et al.Clinical efficacy of ticagrelor in patients undergoing emergency intervention for acute myocardial infarction and its impact on platelet aggregation rate. American Journal of Translational Research 2018;10(7):2175-83. [MEDLINE: ] - PMC - PubMed
Yang 2014a {published data only}
    1. Yang Y, Kong D, Wang C, Chen G, Shan F, Qi K, et al.Inhibition of platelet activation could decrease thrombotic events in hemodialysis PF4/H antibody-positive patients. Renal Failure 2014;36(6):870-6. [MEDLINE: ] - PubMed
Yeh 2017 {published data only}
    1. Yeh CH, Huang TS, Wang YC, Huang PF, Huang TY, Chen TP, et al.Initiation of antiplatelet medication after surgical thrombectomy jeopardized arteriovenous graft longevity. Journal of Vascular Access 2017;18(3):207-13. [MEDLINE: ] - PubMed
Yoshikawa 1999 {published data only}
    1. Ito H, Yoshikawa N.Prospective multicenter controlled therapeutic trial in IgA nephropathy in Japanese children: a preliminary report [abstract no: S-I-2]. Pediatric Nephrology 1992;6(6):C208. [CENTRAL: CN-01658022]
    1. Kamei K, Nakanishi K, Ito S, Saito M, Sako M, Ishikura K, et al.Long-term results of a randomized controlled trial in childhood IgA nephropathy. Clinical Journal of the American Society of Nephrology: CJASN 2011;6(6):1301-07. [MEDLINE: ] - PMC - PubMed
    1. Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M, et al.A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. Journal of the American Society of Nephrology 1999;10(1):101-9. [MEDLINE: ] - PubMed
    1. Yoshikawa N, Ito H.Combined therapy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for paediatric patients with severe IgA nephropathy - is it relevant for adult patients? Nephrology Dialysis Transplantation 1999;14(5):1097-9. [MEDLINE: ] - PubMed
    1. Yoshikawa N, Ito H.Corticosteroids and immunosuppressive drugs [abstract no: S8.2]. Pediatric Nephrology 2001;16(8):C31. [CENTRAL: CN-00448482]
Zhang 2009a {published data only}
    1. Zhang Y, Zhang XD, Ma LL, Guan DL.Relationship between platelet activation and acute rejection after renal transplantation. Transplantation Proceedings 2009;41(5):1547-51. [MEDLINE: ] - PubMed
Zibari 1995 {published data only}
    1. Zibari GB, Gadallah MF, Landreneau MD, McMillian R, Bridges R, Costley K, et al.The efficacy and complications of aspirin versus heparin in postoperative prophylaxis against thrombosis in newly placed hemodialysis access [abstract no: 195]. Journal of the American Society of Nephrology 1995;6(3):507. [CENTRAL: CN-00486594]
Zimmerman 1983 {published data only}
    1. Zimmerman SW, Moorthy AV, Dreher WH, Friedman A, Varanasi U.Prospective trial of warfarin and dipyridamole in patients with membranoproliferative glomerulonephritis. American Journal of Medicine 1983;75(6):920-7. [MEDLINE: ] - PubMed

References to ongoing studies

A‐CLOSE 2019 {published data only}
    1. Kim BK.A randomized comparison of CLOpidogrel monotherapy versus extended dual-antiplatelet therapy beyond 12 months after implantation of drug-eluting StEnts in high-risk lesions or patients; A-CLOSE trial. www.cris.nih.go.kr/cris/search/detailSearch.do/18621 (first received 30 April 2019).
ALTIC 2016 {published data only}
    1. Alexopoulos D.A randomized, pharmacodynamic comparison of low dose ticagrelor to clopidogrel in patients with prior myocardial infarction (ALTIC). www.clinicaltrials.gov/show/nct02663713 (first received 26 January 2016).
ALTIC‐2 2018 {published data only}
    1. Alexopoulos D.Low dose ticagrelor versus low dose prasugrel in patients with prior myocardial infarction (ALTIC-2) [A randomized, pharmacodynamic comparison of low dose ticagrelor (60mg Bid) to low dose prasugrel (5mg od) in patients with prior myocardial infarction]. www.clinicaltrials.gov/show/nct03387826 (first received 2 January 2018 ).
    1. EudraCT2016-004959-80.A randomized, pharmacodynamic comparison of ticagrelor 60mg bid vs prasugrel 5mg in patients with prior myocardial infarction. www.clinicaltrialsregister.eu/ctr-search/trial/2016-004959-80/GR (first received 14 June 2017).
ATTACK 2018 {published data only}40920200
    1. Gallagher H, Roderick P.Aspirin to target arterial events in chronic kidney disease (ATTACK) protocol final version 1.1. www.njl-admin.nihr.ac.uk/document/download/2035436 2018.
ChiCTR1900021393 {published data only}
    1. Zhao J.Antiplatelet therapy for prevention of atherosclerosis in chronic kidney disease: a perspective, multi-center randomized controlled trial [Antiplatelet prophylaxis for atherosclerosis in chronic kidney disease: a multicenter, randomized, pacebo-controlled trial]. www.chictr.org.cn/showproj.aspx?proj=34865 (first received 18 February 2019).
IRCT2013012412256N1 {published data only}
    1. IRCT2013012412256N1.Evaluation the effect of clopidogrel in prevention of access graft thrombosis in upper extrimity in patients undergoing hemodialysis in Emam Reza's Hospital - Kermanshah,2012-2013. www.en.irct.ir/trial/12352 (first received 10 May 2013).
IRCT2013100114333N8 {published data only}
    1. IRCT2013100114333N8.Study of aspirin effects on Permcath function in dialysis patients [Study of effects use and without use of aspirin on Permcath function in dialysis patients]. www.en.irct.ir/trial/13944 (first received 4 October 2013).
IRCT20171023036953N1 {published data only}
    1. IRCT20171023036953N1.The effect of Cilostazol on the mean time of arteriovenous fistula maturation and its comparison to control group in patients with chronic renal failure referring to Emam Reza hospital of Mashhad University of Medical Sciences. www.en.irct.ir/trial/27466 (first received 18 December 2017).
LEDA 2017 {published data only}
    1. Violi F, Targher G, Vestri A, Carnevale R, Averna M, Farcomeni A, et al.Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. The renaL disEase progression by aspirin in diabetic pAtients (LEDA) trial. Rationale and study design. American Heart Journal 2017;189:120-7. [MEDLINE: ] - PubMed
Lemos Cerqueira 2018 {published data only}
    1. Lemos Cerqueira T, Fartolino Guerrero A, Perez Fermin CK, Wang R, Balbino EE, Breeze JL, et al.The use of aspirin to reduce the risk of thrombotic events in patients with end-stage renal disease: protocol for a randomized controlled trial. JMIR Research Protocols 2018;7(8):e10516. [MEDLINE: ] - PMC - PubMed
NCT00272831 {published data only}
    1. Tong PC.The use of cilostazol in patients with diabetic nephropathy [A randomised, double-blind, placebo-controlled study of cilostazol 100 mg twice daily in the treatment of diabetic nephropathy in Hong Kong Chinese]. www.clinicaltrials.gov/show/nct00272831 (first received 9 January 2006).
NCT01198379 {published data only}
    1. Tarng DC.Aspirin in the prevention of cardiovascular events in hemodialysis patients [Efficacy of monitoring of aspirin responsiveness in the prevention of cardiovascular events and decrease in bleeding complications in patients with end-stage kidney disease undergoing hemodialysis]. www.clinicaltrials.gov/ct2/show/NCT01198379 (first received 10 September 2010).
NCT01743014 {published data only}
    1. Bougatsa VF.Ramipril and clopidogrel in oxidative stress, vascular inflammation and endothelial dysfunction in type 2 diabetes and diabetic nephropathy [A prospective, randomized, two period, with an intermediate wash out period, cross-over study to compare the effects of either combined therapy with ramipril and clopidogrel or ramipril monotherapy on oxidative stress, vascular inflammation and endothelial dysfunction in patients with type 2 diabetes and diabetic nephropathy]. www.clinicaltrials.gov/show/nct01743014 (first received 6 December 2012).
NCT02394145 {published data only}
    1. Kim W, Woo JS.Genotype and platelet reactivity in patients on hemodialysis [The relationship between genotype and platelet reactivity in patients treated with ticagrelor versus clopidogrel: PIANO genotype study]. www.clinicaltrials.gov/show/nct02394145 (first received 20 March 2015).
NCT02459288 {published data only}
    1. Liu PY.Platelet resistance with ticagrelor or standard-dose clopidogrel among CKD and ACS patients (APPROVE-SCKD) [A comParison on Platelet Resistance with ticagrelor or standard-dose clopidogrel study among SeVerE Chronic Kidney Disease/end-stage-renal-disease patients with recent acute coronary syndrome]. www.clinicaltrials.gov/show/nct02459288 (first received 2 June 2015).
NCT03039205 {published data only}
    1. Nicolau JC.Platelet aggregation in patients with coronary artery disease and kidney dysfunction taking clopidogrel or ticagrelor [Evaluation of platelet aggregation and adenosine levels in patients with coronary artery disease and chronic kidney dysfunction taking dual antiplatelet therapy with aspirin and clopidogrel or ticagrelor]. www.clinicaltrials.gov/show/nct03039205 (first received 1 February 2017).
NCT03150667 {published data only}
    1. Banerjee S, Baskar A.Study comparing treatment effectiveness of guideline indicated APT for ACS in patients with CKD (CPRS-SKD) [Pragmatic randomized controlled trial comparing treatment effectiveness of guideline indicated anti-platelet therapy for acute coronary syndrome in patients with chronic kidney disease]. www.clinicaltrials.gov/show/nct03150667 (first received 12 May 2017).
NCT03649711 {published data only}
    1. Nishank J.Chronic kidney disease (CKD) platelet study [A mechanistic study in patients with non-dialysis chronic kidney disease to investigate altered platelet response to antiplatelet therapy (CKD-Platelet study)]. www.clinicaltrials.gov/show/nct03649711 (first received 28 August 2018).
Park 2010 {published data only}
    1. Ki YJ, Kwon SA, Kim HL, Seo JB, Chung WY.The prevention of contrast induced nephropathy by sarpogrelate: a prospective randomized controlled clinical trial. Journal of Korean Medical Science 2019;34(40):e261. [MEDLINE: ] - PMC - PubMed
    1. Park K, Chung WY, Seo JB, Kim SH, Zo JH, Kim MA, et al.The prevention of contrast induced nephropathy by sarpogrelate in patients with chronic kidney disease: a study protocol for a prospective randomized controlled clinical trial. Trials [Electronic Resource] 2010;11:122. [MEDLINE: ] - PMC - PubMed
PRASTO‐III 2018 {published data only}
    1. JapicCTI-184141.PRASTRO-III: a double-blind study of CS-747S versus clopidogrel sulfate in patients with thrombotic stroke having risk factors for stroke recurrence. www.clinicaltrials.jp/cti-user/trial/ShowDirect jsp?japicId=JapicCTI-184141 (first received 25 October 2018).
SERENADE 2015 {published data only}
    1. Lee SA, Suh JW, Park JJ, Yoon CH, Cho YS, Youn TJ, et al.Study design of the influence of SErotonin inhibition on patients with RENAl impairment or diabetes undergoing drug-eluting stent implantation (SERENADE) study: A multicenter, open-label, prospective, randomized study. Contemporary Clinical Trials 2015;43:20-4. [MEDLINE: ] - PubMed
SONATA 2013 {published data only}
    1. Choi DS.Effect of sarpogrelate on the nephropathy in type 2 diabetes (SONATA study). www.clinicaltrials.gov/show/NCT01869881 (first received June 5 2013).
TROUPER 2020 {published data only}
    1. Laine M, Lemesle G, Burtey S, Cayla G, Range G, Quaino G, et al.TicagRelor Or Clopidogrel in severe or terminal chronic kidney patients Undergoing PERcutaneous coronary intervention for acute coronary syndrome: The TROUPER trial. American Heart Journal 2020;225:19-26. [MEDLINE: ] - PubMed
TWILIGHT 2016 {published data only}
    1. Pandit N, Parakh N, Gupta S.TWILIGHT Study The anti platelet therapy with both ticagrelor and aspirin for 3 months after coronary intervention followed by ticagrelor only for a year rather than both aspirin and ticagrelor is better in reducing the ischemic events in high risk patients. www.ctri.nic.in/Clinicaltrials/pdf_generate php?trialid=12839&EncHid=&modid=&compid=%27,%2712839det%27 (first received 13 July 2016).
UMIN000003891 {published data only}
    1. UMIN000003891.Examination concerning utility and safety of cilostazol use in patients with PAD conplicated to CKD. www.upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view cgi?recptno=R000003304 (first received 15 July 2010).
VA PTXRx 2018 {published data only}
    1. Leehey DJ, Carlson K, Reda D, Polzin L, Clise CE, Paine T, et al.Pentoxifylline in diabetic kidney disease: the VA pentoxifylline in diabetic kidney disease PTXRX study [abstract no: PUB074]. Journal of the American Society of Nephrology 2019;30(Abstract Suppl):1092. [EMBASE: 633771821]
    1. Leehey DJ, Craig I, Reda D, Carlson K, Conner TA, Agarwal R, et al.Design of pentoxifylline in diabetic kidney disease (VA PTXRx) [abstract no: SA-PO154]. Journal of the American Society of Nephrology 2018;29(Abstract Suppl):775. [EMBASE: 633732689]

Additional references

Aakhus 1999
    1. Aakhus S, Dahl K, Wideroe TE.Cardiovascular morbidity and risk factors in renal transplant patients. Nephrology Dialysis Transplantation 1999;14(3):648-54. [MEDLINE: ] - PubMed
Amann 2003
    1. Amann K, Tyralla K, Gross ML, Eifert T, Adamczak M, Ritz E.Special characteristics of atherosclerosis in chronic renal failure. Clinical Nephrology 2003;60 Suppl 1:S13-21. [MEDLINE: ] - PubMed
ANZDATA 2019
    1. Australia & New Zealand Dialysis & Transplant Registry.The 42nd Annual Report 2019 (Data to 2018). www.anzdata.org.au/?s=annual+report&data-group=anzdata (accessed 24 October 2021).
ATT 2002
    1. Antithrombotic Trialists' Collaboration.Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.[Erratum in: BMJ 2002 Jan 19;324(7330):141]. BMJ 2002;324(7329):71-86. [MEDLINE: ] - PMC - PubMed
ATT 2009
    1. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al.Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373(9678):1849-60. [MEDLINE: ] - PMC - PubMed
AusDiab 2003
    1. Chadban SJ, Briganti EM, Kerr PG, Dunstan DW, Welborn TA, Zimmet PZ, et al.Prevalence of kidney damage in Australian adults: The AusDiab kidney study. Journal of the American Society of Nephrology 2006;14(7 Suppl 2):S131-8. [MEDLINE: ] - PubMed
Berger 2003
    1. Berger AK, Duval S, Krumholz HM.Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. Journal of the American College of Cardiology 2003;42(2):201-8. [MEDLINE: ] - PubMed
Best 2008
    1. Best PJ, Steinhubl SR, Berger PB, Dasgupta A, Brennan DM, Szczech LA, et al.The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal 2008;155(4):687-93. [MEDLINE: ] - PubMed
Bonomini 1986
    1. Bonomini V, Vangelista A, Stefoni S, Scolari MP, Frasca GM, Raimondi C.Use of defibrotide in renal transplantation in man. Haemostasis 1986;16 Suppl 1:48-50. [MEDLINE: ] - PubMed
CARI 2000
    1. Caring for Australasians with Renal Impairment (CARI).Vascular access. www.cariguidelines.org/guidelines/dialysis/vascular-access/ (accessed 24 October 2021).
Casas 2005
    1. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, et al.Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366(9502):2026-33. [MEDLINE: ] - PubMed
Coleman 2010
    1. Coleman CI, Tuttle LA, Teevan C, Baker WL, White CM, Reinhart KM.Antiplatelet agents for the prevention of arteriovenous fistula and graft thrombosis: a meta analysis. International Journal of Clinical Practice 2010;64(9):1239-44. [MEDLINE: ] - PubMed
Collins 2003
    1. Collins AJ.Cardiovascular mortality in end-stage renal disease. American Journal of the Medical Sciences 2003;325(4):163-7. [MEDLINE: ] - PubMed
Curtis 2005
    1. Curtis BM, Parfrey PS.Congestive heart failure in chronic kidney disease: disease-specific mechanisms of systolic and diastolic heart failure and management. Cardiology Clinics 2005;23(3):275-84. [MEDLINE: ] - PubMed
de Jager 2009
    1. Jager DJ, Grootendorst DC, Jager KJ, Dijk PC, Tomas LM, Ansell D, et al.Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009;302(16):1782-9. [MEDLINE: ] - PubMed
Dikow 2005
    1. Dikow R, Zeier M, Ritz E.Pathophysiology of cardiovascular disease and renal failure. Cardiology Clinics 2005;23(3):311-7. [MEDLINE: ] - PubMed
Fields 2004
    1. Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P.The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension 2004;44(4):398-404. [MEDLINE: ] - PubMed
Foley 1995
    1. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, et al.Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney International 1995;47(1):186-92. [MEDLINE: ] - PubMed
Fort 2005
    1. Fort J.Chronic renal failure: a cardiovascular risk factor. Kidney International - Supplement 2005;99:S25-9. [MEDLINE: ] - PubMed
Go 2004
    1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY.Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.[Erratum in: N Engl J Med. 2008;18(4):4]. New England Journal of Medicine 2004;351(13):1296-305. [MEDLINE: ] - PubMed
GRADE 2008
    1. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al.GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6. [MEDLINE: ] - PMC - PubMed
GRADE 2011a
    1. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al.GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94. [MEDLINE: ] - PubMed
GRADE 2011b
    1. GRADE Working Group.Grading of Recommendations Assessment, Development and Evaluation (GRADE). www.gradeworkinggroup.org (last accessed 24 October 2021).
GRADE 2011c
    1. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al.GRADE guidelines 6. Rating the quality of evidence--imprecision. Journal of Clinical Epidemiology 2011;64(12):1283-93. [MEDLINE: ] - PubMed
Gurbel 2019
    1. Gurbel PA, Fox KA, Tantry US, Ten Cate H, Weitz JI.Combination antiplatelet and oral anticoagulant therapy in patients with coronary and peripheral artery disease. Circulation 2019;139(18):2170-85. [MEDLINE: ] - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG.Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: ] - PMC - PubMed
Higgins 2020
    1. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors).Cochrane Handbook for Systematic Reviewsof Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.
Hung 2014
    1. Hung CC, Yang ML, Lin MY, Lin HY, Lim LM, Kuo HT, et al.Dipyridamole treatment is associated with improved renal outcome and patient survival in advanced chronic kidney disease. Kaohsiung Journal of Medical Science 2014;30(12):599-607. [MEDLINE: ] - PMC - PubMed
Kasiske 2000
    1. Kasiske BL.Cardiovascular disease after renal transplantation. Seminars in Nephrology 2000;20(2):176-87. [MEDLINE: ] - PubMed
Kaw 2006
    1. Kaw D, Malhotra D.Platelet dysfunction and end-stage renal disease. Seminars in Dialysis 2006;19(4):317-22. [MEDLINE: ] - PubMed
Keith 2004
    1. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH.Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Archives of Internal Medicine 2004;164(6):659-63. [MEDLINE: ] - PubMed
Koren‐Morag 2006
    1. Koren-Morag N, Goldbourt U, Tanne D.Renal dysfunction and risk of ischemic stroke or TIA in patients with cardiovascular disease. Neurology 2006;67(2):224-8. [MEDLINE: ] - PubMed
Mann 2001
    1. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S.Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Annals of Internal Medicine 2001;134(8):629-36. [MEDLINE: ] - PubMed
McCullough 2002
    1. McCullough PA, Sandberg KR, Borzak S, Hudson MP, Garg M, Manley HJ.Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. American Heart Journal 2002;144(2):226-32. [MEDLINE: ] - PubMed
Mokdad 2003
    1. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al.Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289(1):76-9. [MEDLINE: ] - PubMed
Mosenkis 2004
    1. Mosenkis A, Berns JS.Use of low molecular weight heparins and glycoprotein IIb/IIIa inhibitors in patients with chronic kidney disease. Seminars in Dialysis 2004;17(5):411-5. [MEDLINE: ] - PubMed
NHANES 2010
    1. National Health and Nutrition Examination Survey. www.cdc.gov/nchs/nhanes.htm (accessed 24 October 2021).
Norris 2006
    1. Norris K, Bourgoigne J, Gassman J, Hebert L, Middleton J, Phillips RA, et al.Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. American Journal of Kidney Diseases 2006;48(5):739-51. [MEDLINE: ] - PubMed
Oelz 1979
    1. Oelz O.Action mechanism and clinical indications for thrombocyte aggregation inhibitors [Wirkungsmechanismus und klinische Indikationen der Thrombozytenaggregationshemmer]. Schweizerische Medizinische Wochenschrift. Journal Suisse de Medecine 1979;109(10):348-53. [MEDLINE: ] - PubMed
Ojo 2000
    1. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK.Long-term survival in renal transplant recipients with graft function. Kidney International 2000;57(1):307-13. [MEDLINE: ] - PubMed
Osborn 2008
    1. Osborn G, Escofet X, Da Silva A.Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No: CD002786. [DOI: 10.1002/14651858.CD002786.pub2] - DOI - PubMed
Remppis 2008
    1. Remppis A, Ritz E.Cardiac problems in the dialysis patient: beyond coronary disease. Seminars in Dialysis 2008;21(4):319-25. [MEDLINE: ] - PubMed
Remuzzi 1988
    1. Remuzzi G.Bleeding in renal failure. Lancet 1988;1(8596):1205-8. [MEDLINE: ] - PubMed
Ruilope 2001
    1. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, et al.Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. Journal of the American Society of Nephrology 2001;12(2):218-25. [MEDLINE: ] - PubMed
Sarnak 2003
    1. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al.Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003;42(5):1050-65. [MEDLINE: ] - PubMed
Scheen 2008
    1. Scheen AJ.Medications in the kidney. Acta Clinica Belgica 2008;63(2):76-80. [MEDLINE: ] - PubMed
Schror 1997
    1. Schrör K.Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Seminars in Thrombosis & Hemostasis 1997;23(4):349-56. [MEDLINE: ] - PubMed
Schunemann 2020a
    1. Schünemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, et al.Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. www.training.cochrane.org/handbook.
Schunemann 2020b
    1. Schünemann HJ, Vist GE, Higgins JP, Santesso N, Deeks JJ, Glasziou P, et al.Chapter 15: Interpreting results and drawing conclusions. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.
Song 2003
    1. Song F, Altman DG, Glenny AM, Deeks JJ.Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003;326(7387):472. [MEDLINE: ] - PMC - PubMed
Stangal 2010
    1. Stangl PA, Lewis S.Review of currently available GP IIb/IIIa inhibitors and their role in peripheral vascular interventions. Seminars in Interventional Radiology 2010;27(4):412-21. [MEDLINE: ] - PMC - PubMed
Su 2019
    1. Su X, Yan B, Wang L, LV J, Cheng H, Chen Y.Effect of antiplatelet therapy on cardiovascular and kidney outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. BMC Nephrology 2019;20(1):309. [MEDLINE: ] - PMC - PubMed
Taji 2006
    1. Taji Y, Kuwahara T, Shikata S, Morimoto T.Meta-analysis of antiplatelet therapy for IgA nephropathy. Clinical & Experimental Nephrology 2006;10(4):268-73. [MEDLINE: ] - PubMed
UK Renal Association 2010
    1. UK Renal Association.Cardiovascular disease in CKD. www.renal.org/Clinical/GuidelinesSection/CardiovascularDiseaseInCKD.aspx... (accessed 24 October 2021).
USRDS 2010
    1. US Renal Data System.USRDS 2010 Annual Data Report. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. www.usrds.org/annual-data-report/previous-adrs/ (accessed 24 October 2021).
Wattanakit 2008
    1. Wattanakit K, Cushman M, Stehman-Breen C, Heckbert SR, Folsom AR.Chronic kidney disease increases risk for venous thromboembolism. Journal of the American Society of Nephrology 2008;19(1):135-40. [MEDLINE: ] - PMC - PubMed
Weiner 2004a
    1. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, et al.Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. Journal of the American Society of Nephrology 2004;15(5):1307-15. [MEDLINE: ] - PubMed
Weiner 2004b
    1. Weiner DE, Tighiouart H, Stark PC, Amin MG, MacLeod B, Griffith JL, et al.Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. American Journal of Kidney Diseases 2004;44(2):198-206. [MEDLINE: ] - PubMed
Woo 2011
    1. Woo JS, Kim W, Lee SR, Jung KH, Kim WS, Lew JH, et al.Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney disease (PIANO-2 CKD) randomized study. American Heart Journal 2011;162(6):1018-25. [MEDLINE: ] - PubMed
Zwaginga 1991
    1. Zwaginga JJ, IJsseldijk MJ, Groot P G, Vos J, Bos Kuil RL, Sixma JJ.Defects in platelet adhesion and aggregate formation in uremic bleeding disorder can be attributed to factors in plasma. Arteriosclerosis & Thrombosis 1991;11(3):733-44. [MEDLINE: ] - PubMed

References to other published versions of this review

Palmer 2012
    1. Palmer SC, Di Micco L, Razavian M, Craig JC, Ravani P, Perkovic V, et al.Antiplatelet therapy to prevent hemodialysis vascular access failure: systematic review and meta-analysis. American Journal of Kidney Diseases 2013;61(1):112-22. [MEDLINE: ] - PubMed
Palmer 2013
    1. Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, et al.Antiplatelet agents for chronic kidney disease. Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No: CD008834. [DOI: 10.1002/14651858.CD008834.pub3] - DOI - PubMed
Razavian 2010
    1. Razavian M, Di Micco L, Palmer SC, Craig JC, Perkovic V, Zoungas S, et al.Antiplatelet agents for chronic kidney disease. Cochrane Database of Systematic Reviews 2010, Issue 11. Art. No: CD008834. [DOI: 10.1002/14651858.CD008834] - DOI - PubMed

Publication types

MeSH terms

Substances

Associated data